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Introduction 
 
1. Tumor-specific chromosomal translocations 
 
1.1 General aspects 
 
Cancer is due to acquired genetic changes, sometimes associated with inherited 
predisposing mutations. Hypothesis that chromosomal changes are responsible for 
neoplasia was first proposed by Theodor Boveri in 1914 [1] but it was completely 
accepted with improvements in cytogenetic and molecular techniques. Translocations 
together with deletions and inversions represent the three main cytogenetic changes in 
cancer. Translocations can be divided in specific, when consistently found in a certain 
tumor types, and idiopathic, when observed in the tumor from one patient [2]. Up until 
recently, importance of tumor-specific translocations was mainly diagnostic but the 
more recent characterization of these rearrangements has provided important insights 
into the neoplastic process [3]. Consequences of chromosomal translocations are 
potentially two: activation of genes located at or near the breakpoints that are pivotal in 
the control of cell growth and differentiation or generation of a chimaeric gene resulting 
from fusion between two unrelated genes positioned at each of the involved 
chromosomal breakpoints. In both of the cases, a factor with altered expression or 
function is produced and it cooperates in establishing a transformed phenotype. In some 
cases, translocations can inactivate oncosuppressor genes such as repression of TEL1 as 
a consequence of the TEL1-AML translocation [4]. The first described translocation was 
the Philadelphia chromosome, a reciprocal chromosomal translocation involving 
chromosomes 9 and 22 in chronic myelogenous leukemia (CML) [5]. Subsequently, a 
translocation between chromosomes 8 and 14 was discovered in Burkitt’s lymphoma [6] 
where c-MYC oncogene translocates to the immunoglobulin heavy chain loci on 
chromosome 14 [7]. These discoveries stimulated interest in cancer cytogenetics and, as 
a consequence, information on chromosomal aberrations in cancer has increased over 
the past two decades. In the early 1990s, specific translocations were found in sarcomas 
including Ewing sarcoma, myxoid liposarcoma and synovial sarcomas. Until that 
period, it was believed that chromosomal translocations were restricted to lymphoid 
cancers and few sarcomas but subsequent studies showed that carcinomas can express 
chromosomal translocations. The first example was the fusion between RET gene 
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encoding a tyrosine kinase receptor with the CCDC6 gene in papillary thyroid 
carcinoma [8]. Afterwards, other gene fusions have been discovered in carcinomas. 
Particularly, important fusion genes have been recently identified in prostate and lung 
cancer.  
Molecular cytogenetic techniques including fluorescence in situ hybridization (FISH), 
multicolour FISH and array-based comparative genomic hybridization dramatically 
improved analysis of chromosomal breakpoints that now can be mapped very precisely 
[9]. Cytogenetic characterization allowed identification of almost 337 genes involved in 
fusions in neoplastic disorders and they represent a substantial proportion of all mutated 
genes implicated in oncogenesis [9]. Many of these chromosomal translocations are 
associated with distinct tumor types, clinical features and characteristic gene expression 
profiles. This information has become an important tool in the management of cancer 
patients helping to establish a correct diagnosis, select appropriate treatment, and 
predict outcome [9].  As a consequence, fusion genes represent useful biomarkers which 
identification represents a remarkable advantage in a certain tumor type.    
 
 
1.2 Gene fusions in haematological disorders  
 
Leukaemias and limphomas, together constituting 8% of all cancers, harbor 
translocations in almost all cases, representing 75% of all gene fusions known un human 
neoplasia. These high percentages lead to opinion that these disorders are exclusively 
caused by fusion genes. Actually, prevalence of most individual gene fusions is very 
low and few well-known specific changes are observed in 100% of cases and represent 
exceptions: BCR-ABL in CML, IGH-CCND1 in mantle cell lymphoma, MYC 
deregulation in Burkitt’s lymphoma and PML-RARA in acute promyelocytic leukaemia 
(APL). CML  is characterized by a translocation between ABL gene on chromosome 9 
and BCR gene promoter on chromosome 22. This results in the formation of a unique 
in-frame fusion mRNA and a constitutively activated protein tyrosine kinase that was 
shown to be oncogenic [10]. Subsequently, the tyrosine kinase inhibitor imatinib 
mesylate, specific for the ABL, was developed [11] and preclinical and clinical trials 
demonstrated its high efficacy becoming a new standard treatment for CML patients 
[12]. Burkitt’s lymphoma is a B cell tumor containing the t(8;14) translocation in 70% 
of cases and resulting in over-expression of c-MYC. Several therapeutic approaches 
have been developed to target MYC-dependent tumors including inhibitors of 
transcriptional machinery, inhibitors of MYC dimerization which prevents its DNA 
binding, blockade of MYC stability but clinical trials evaluating effectiveness in 
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lymphoid malignancies are lacking [13]. Chromosomal translocation involving 
chromosomes 11 and 14 in mantle cell lymphoma results in constitutional over-
expression of cyclin D1 and, consequently, cell cycle deregulation. Nowadays, detection 
of t(11;14) or cyclin D1 over-expression represent crucial features for a correct 
diagnosis [14]. In over 98% of APL patients, a specific chromosomal translocation fuses 
PML gene on chromosome 15 to the RARA gene on chromosome 17 resulting in 
PML/RARA fusion protein which is the molecular determinant of the disease [15] and a 
useful tool for tumor diagnosis [16].      
 
 
1.3 Gene fusions in sarcomas 
 
Bone and soft tissue sarcomas represent a clinically and morphologically heterogeneous 
group of neoplasms of mesenchymal or neuroectodermal origin. The overall fraction of 
sarcomas with chimeric genes is 15 to 20%. Between sarcomas presenting chromosomal 
translocations, Ewing sarcoma, myxoid liposarcomas and synovial sarcomas harbor 
chimeric genes in 100% of cases [9]. Ewing sarcoma specific translocation involves 
EWSR1 gene on chromosome 22 and one of the ETS transcription factor genes, 
particularly FLI1, located on chromosome 11, in 85% of cases, or ERG, on chromosome 
21, in 11% of cases. EWS-ETS fusion gene results in a chimeric protein with aberrant 
transcriptional activity. Since its discovery, EWS-FLI1 represented a fundamental tool 
for Ewing sarcoma diagnosis and a key element for a better understanding of tumor 
biology. Several studies demonstrated its importance in induction of a transformed 
phenotype mainly through identification of its target genes. Being exclusively located 
within the tumor and driving cell transformation, EWS-FLI1 represents an excellent 
therapeutic target and some compounds were developed in the past years in order to 
specifically block it. Particularly, the small molecule YK-4-279, disrupting interaction 
between EWS-FLI1 and RNA Helicase A (RHA), which is a critical mechanism for 
EWS transformation [17], was shown to induce apoptotic cell death [18] in preclinical 
studies but it never entered the clinic. Currently, additional preclinical studies are 
ongoing testing its efficacy alone or in combination with other compounds with the 
purpose to optimize its use [19-21]. Myxoid liposarcoma is characterized by a 
translocation fusing FUS gene, on chromosome 12, and CHOP gene on chromosome 
16. The fusion FUS-CHOP protein functions as abnormal transcription factor and its 
relevance in the pathogenesis of myxoid liposarcoma is well established [22]. Recent 
evidences demonstrated that myxoid liposarcoma is particularly sensitive to Trabectedin 
(ET-734, Yondelis), a marine alkaloid which is cytotoxic against a variety of tumor cell 
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lines [23] and human tumor xenografts in vivo [24]. In vitro studies demonstrated that 
the high sensitivity of myxoid liposarcoma to this agent is due to the ability of 
Trabectedin to act as a differentiating agent by blocking the transactivating capability of 
FUS-CHOP [25, 26]. Clinical trials confirmed the high efficacy of Trabectedin in 
patients [27].  
The molecular hallmark of synovial sarcoma is a pathognomonic reciprocal 
translocation leading to the fusion of SS18 to one of the homologs SSX genes, 
generating oncogenic SS18-SSX fusion proteins with aberrant transcriptional activity 
[28]. The specific biological function and the mechanism of action of SS18-SSX remain 
to be defined but it has a crucial role in tumorigenesis and progression. No specific 
agent has been developed jet to directly inhibit SS18-SSX as it is part of regulatory 
active complexes but recently some studies have been focused on inhibition of SS18-
SSX-mediated pathways such as Wnt/β-catenin signaling. Preliminary data demonstrate 
a good in vitro response to these agents [28].  
 
    
1.4 Gene fusions in carcinomas 
 
Occurrence of gene fusions in malignant epithelial tumors is generally rare and this lead 
to the commonly view that chromosomal translocations have a minor role in the 
pathogenesis of carcinomas [9]. Actually, carcinomas are characterized by gene 
rearrangements as well but limitations of available techniques and the individual rarity 
of these alterations made them more difficult to detect. Overall, almost all lymphomas 
harbor translocations, whereas only one-fourth of all sarcomas is reported to possess the 
same. Gene fusion have been recently discovered in carcinomas so that the exact 
percentage of carcinomas harboring fusion genes is not clear. The most remarkable 
recently discovered fusion genes in epithelial tumors include TMPRSS2-ERG in prostate 
cancer and EML4-ALK in lung cancer. Prostate cancer is the first common cancer 
associated with a high frequency to a gene fusion as almost 70% of cases present this 
rearrangement. Through bioinformatic tools, Tomlins et al. in 2005 noticed a strong 
over-expression of ETS transcription factor genes, ERG and ETV1, in prostate cancer 
specimens [29]. Subsequently, the genes were found to be fused with the 5’ part of the 
prostate-specific gene TMPRSS2 located on chromosome 21. The result is an androgen-
regulated over-expression of ERG or ETV1 which can stimulate transcription of target 
genes for cell growth, invasion and metastases and promote cancer progression [30, 31]. 
At clinical level, TMPRSS2-ERG was found to improve detection of clinically 
significant prostate cancer when combined with other biomarkers evaluation such as 
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PCA3 or SPINK1 [32-34]. In addition, prognostic relevance of TMPRSS2-ERG was 
investigated in several epidemiological studies, giving controversial results. The 
restricted expression of TMPRSS2-ERG to cancer cell made it a suitable therapeutic 
target [35]. Currently, TMPRSS2-ERG inhibition in vitro has been demonstrated to 
inhibit tumor growth. Specific siRNA via liposomal nanovector have been proposed 
[36] representing a potential efficacious treatment with low toxicity for prostate cancer 
patients.  
Fusion between the anaplastic lymphoma kinase gene (ALK) and the echinoderm 
microtubule-associated protein-like 4 gene (EML4) has been detected in a subset of non-
small cell lung cancers (NSCLCs). The EML4-ALK fusion gene encodes a fusion 
protein retaining the kinase domain of ALK [37]. Oncogenic fusion genes have been 
detected in approximately 2-7% of NSCLC patients. EML4-ALK defines a molecular 
subset of patients with distinct clinical characteristics and with a relevant therapeutic 
option in crizotinib, a small molecule inhibitor of both ALK and c-MET, with high 
tolerability and robust antitumor activity as demonstrated by clinical trials. Nowadays, 
crizotinib is a new standard of care for patients with advanced, EML2-ALK-positive, 
NSCLC [38]. 
 
 
1.5 ETS-associated translocations 
 
The ETS transcription factors family was established from the v-ets oncogene, 
discovered as part of the transforming fusion protein of E26 avian replication-defective 
retrovirus. The v-ets oncogene was found to be able to transform fibroblasts, 
myeloblasts, and erythroblasts in vitro. Today, the ETS family is known as one of the 
largest families of transcriptional regulators, with various functions and activities. In 
human, 27 ETS members have been identified and they are characterized by the ETS 
domain, a 85 amino acids conserved sequence with DNA-binding capability. In 
particular, this domain is composed of three alpha helices and a four-stranded, beta 
sheet recognizing a core GGAA/T sequence (Ets binding site). ETS factors act as 
positive or negative regulators of expression of genes that are involved in various 
biological processes including cell proliferation, differentiation, hematopoiesis, 
apoptosis, metastasis, tissue remodeling, angiogenesis and transformation [39]. The 
importance of ETS genes in cancer was early demonstrated by in vitro and in vivo 
studies showing cellular transformation induced by ETS1, ETS2 and ERG [40-42]. In 
addition, ETS relevance in cancer has been demonstrated by the observation that ETS 
genes are frequently mutated in tumors including frequent location at translocation 
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breakpoints. Particularly, ERG involvement in chromosomal rearrangements was 
described in leukaemias and solid tumors including sarcomas and carcinomas. In 
leukaemias, FUS gene on chromosome 16 was described to be fused with ERG in acute 
myeloid leukaemia [43, 44]. The product is the FUS-ERG fusion protein, an early event 
in cancer progression with established oncogenic properties including inhibition of 
differentiation into neutrophils of a mouse myeloid precursor cell line [45]. As 
previously mentioned, chromosomal rearrangements involving ERG have been also 
described in Ewing sarcoma, where the ETS generates fusion genes with EWS driving 
cell transformation, and prostate cancer, where the ETS genes fuse with androgen-
related TMPRSS2. Considering ETS involvement in chromosomal translocations as a 
shared mechanism between different tumor types, identification of common or 
distinctive mechanisms sustained by ETS rearrangement that could be relevant for 
tumor biology and clinical management of tumors represents the objective of several 
studies, including the one here presented.  
 
 
 
2. Ewing sarcoma 
 
2.1  General characteristics 
 
In 1921, Dr. James Ewing described for the first time a lesion that he named a “diffuse 
endothelioma of bone” [46] and that today is known as Ewing sarcoma (ES). ES 
belongs to the Ewing’s sarcoma family tumors (ESFT) comprehending osseous ES, 
extra-skeletal ES, Askin tumor and peripheral primitive neuroectodermal tumor (PNET) 
[47, 48]. ES is a rare highly aggressive and poor differentiated disease composed by 
small round cells. It mostly affects bone but can also involve soft tissues including 
kidney, lung, bladder, prostate. From a biological point of view, ESFT are characterized 
by a specific translocation resulting in most of the cases in the EWS-FLI1 chimeric 
transcription factor that is transforming in cells. 
 
2.2  Epidemiology and risk 
 
ES is the second most common tumor of bone after osteosarcoma among children and 
young adults, with an annual incidence rate of three per million. Some evidences show 
that boys are more commonly affected than girls with a ratio of 1.5:1. In 90% of the 
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cases, patients are between the ages of 5 and 20 years while is rare in individuals older 
than 40 and younger than 5 years. No environmental factor has been identified as a risk 
factor for this tumor [49] and there is no evidence regarding familiar predisposition [50] 
beside some studies reported an increased risk of neuroectodermal tumors and stomach 
cancer in family members of ES patients [51] or congenital mesenchymal defects in ES 
patients [52]. Ethnicity represents an important epidemiologic factor with the highest 
risk in Caucasians more than Africans and Asians. Some studies demonstrated an 
increased risk of secondary cancers after ES treatment including radiation-induced 
osteosarcoma or therapy-related acute myeloid leukemia but incidence of ES as a 
second tumor after therapy is rare [53, 54].  
 
2.3  Localization, histopathology and staging 
 
ES mainly arises as a primitive tumor of flat, short and long bones. In the appendicular 
skeleton, femur is the most common localization followed by tibia, humerus, fibula, and 
forearm bones. In the trunk, the most frequent localization is the pelvis, followed by 
vertebrae and sacrum, scapula, ribs, and clavicle. In long bones ES can arise from 
midshaft but may involve a larger portion or even the entire bone. Skull, hands and feet 
involvement in rare. More frequently, ES presents as a permeative, infiltrative, poorly 
defined osteolysis. The cortex is normally breached or destroyed by the tumor while 
rarely the tumor remains intramedullary. ES is very soft, grayish and can be hyperemic 
or hemorrhagic. In the center it is normally necrotic, with a semiliquid appearance. 
Microscopically, the tumor is composed of small round cells closely packed and without 
matrix. Cytoplasm is scarce, pale, granular, and clear to eosinophilic with poorly 
defined limits. Nuclei are round/oval, with a distinct nuclear membrane and powder-like 
chromatin, with one or more tiny nucleoli (Figure 1). Current staging of ES was 
proposed by Enneking: EW I, solitary intraosseous; EW II, solitary extraosseous; EW 
III, multicentric, skeletal; EW IV, distant metastases [55].  
 
11 
 
 
     Figure 1. Histologic and radiographic appearance of Ewing sarcoma [56].  
 
2.4  Course and diagnosis 
 
Pain is the earliest symptom of ES together with swelling in a bone or joint. Systemic 
symptoms such as weight loss and fever can be associated but sometimes lead to 
erroneous diagnosis. ES usually displays an aggressive growth beside some cases where 
ES remains intraosseous have been described. Metastases from ES at presentation are 
about 20 to 25% and sites of metastases are the lungs in 50 percent of cases, bone in 25 
percent of cases, and bone marrow in 25 percent of cases. Limph nodes and brain can 
also be involved in metastases from ES [56]. In some cases, presence of multiple bone 
lesions at diagnosis makes difficult to distinguish between metastases and a multicentric 
origin of primitive tumor. The five-year survival rate is 60% in patients who present 
with primitive tumor while it decreases at 30% in patients with metastasis. The ten-year 
survival rate accounts 55% [57]. The poor prognosis of ES is due to both tumor 
aggressiveness, as it displays an elevated rate of recurrence and metastases, and 
secondary diseases caused by chemotherapy and radiotherapy [58]. Diagnosis of ES 
requires a multidisciplinary approach involving immunological, genetic and imaging 
techniques. Absence of exclusive morphologic characteristics of ES made the diagnosis 
of this tumor difficult up to the 90’s when EWS-FLI1 fusion gene was discovered and, 
consequently, the molecular analysis was introduced in the clinical practice. Biopsy 
from at least two sites of the tumor should be obtained for pathological, cytogenetic and 
molecular studies. In addition, as ES metastatizes to bone marrow, patients must 
undergo bone marrow aspiration and biopsy at two or more sites [56]. Plain radiographs 
and magnetic resonance imaging of the entire affected bone should be included in the 
evaluation.  
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2.5  Cell of origin 
 
The histogenesis of ES remains unknown despite the efforts and numerous studies 
performed in this field. Many groups proposed different origins of this tumor but the 
most accredited hypothesis are two: neural and mesenchymal histogenesis. The neural 
hypothesis arises from the observation that EWS-FLI1 rearrangement is a common 
feature between ES of bone and PNET. In addition, different studies evidenced that both 
osseous [59] and extra-osseous [60] ES cell lines undergo neural differentiation upon 
stimulation with differentiating agents. In particular, the study from Cavazzana et al. 
evidenced that, in five osseous ES cell lines, treatment with AMPc +/- NGF induced 
marked morphologic evidence of neural differentiation including neural filaments, 
synthesis of neuron-specific enzymes such as cholinesterases and NSE, and expression 
of neural tissue cytoskeleton proteins (NFTP). In that study, the authors strongly 
provided evidences for neural histogenesis of ES and suggested a close relationship 
between ES and peripheral neural tumors [59]. In the study from Noguera et al., the 
authors evaluated the capability of three extra-osseous ES cell lines to differentiate 
toward a neural and muscular direction upon stimulation with dibutyryl cyclin 
adenosine-monophosphate (db cAMP) and 5-azacytidine, respectively. A neural but not 
myoblastic differentiation was observed as all the cell lines expressed neural markers 
including chromogranin, S-100 protein, and glial fibrillary acidic protein [60]. More 
recently, it has been demonstrated that forced expression of EWS-FLI1 in a 
rhabdomyosarcoma cell line induced cell morphology changes resembling ES cell 
particularly through modulation of EWS-FLI1 target genes involved in neural crest 
differentiation [61]. In parallel, several studies explored the hypothesis of a 
mesenchymal origin of ES particularly through modulation of EWS-FLI1 expression in 
different cellular models. Studies conducted on mesenchymal stem cells (MSC) 
evidenced that forced expression of EWS-FLI1 blocked differentiation along osteogenic 
and adipogenic lineage, accordingly with the undifferentiated phenotype of ES, [62] as 
well as myogenic differentiation in a murine myoblast cell line [63]. Successive studies 
confirmed that marrow-derived mesenchymal cells could be the progenitor of ES as 
EWS-FLI1 expression induces acquisition of EWS-specific morphological features [64] 
and because these cells are particularly permissive for EWS-FLI1 oncogenic 
transformation also as unique event [64, 65]. On the opposite site, silencing of EWS-
FLI1 in different ES cell lines caused convergence toward the MSCs gene profile and 
induced expression of specific MSC markers such as CD44, CD54, CD59, CD73. 
Moreover, EWS-FLI1 silencing induces ES cells to differentiate along the adipogenic or 
adipogenic lineage upon treatment with appropriate differentiation agents [66].       
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2.6  Molecular biology of Ewing sarcoma    
 
Conventionally, bone sarcomas or soft tissues can be cytogenetically distinguished in 
two groups: one group characterized by simple near-diploid karyotype with few 
chromosome rearrangements and one group with a complex karyotype and a severe 
disturbance in genomic stability [67]. ES belongs to the simple karyotype sarcomas 
group as it carries a tumor-specific recurrent chromosome aberration leading to the 
fusion of the EWSR1 gene with one of several members of the ETS family of 
transcription factor [68], as previously cited. In 85% of the cases, patients express the 
t(11;22)(q24;q12) translocation which product is EWS-FLI1 chimeric protein [69]. In 
10-15% of the cases, the translocation t(21;12)(22;12)  leads to the fusion of EWSR1 to 
ERG while others translocations are rare and account 1 to 5% of the cases (Table 1).   
 
 
                Table 1. Translocations and fusion gene in ESFT. 
 
 
 
 
 
 
 
The chimera holds the amino terminus of EWSR1 gene and the carboxy terminus of the 
ETS gene acting as an aberrant transcription factor. EWSR1 gene, located on 
chromosome 22, belongs to a subgroup of RNA-binding proteins called the TET family 
and is ubiquitously expressed. Proteins of this family hold a central RNA-binding motif 
and three regions rich in glycine, arginine and proline, interacting with RNA [69].  EWS 
is a nuclear protein that appears to be recruited to promoter regions acting as a 
promoter-specific transactivator upon association with other factors [49] such as RNA 
Translocation Fusion gene Frequency (%) 
t(11;22)(q24;q12) EWS-FLI1 85 
t(21;22)(q22;q12) EWS-ERG 10 
t(7;22)(p22;q12) EWS-ETV1 <1 
t(17;22)(q21;q12) EWS-ETV4 <1 
t(2;22)(q33;q12) EWS-FEV <1 
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polymerase II, TFIID and CBP/p300 [70]. In addition, the N-terminus domain is rich in 
glutamine and it stimulates transcription if fused with DNA-binding domains, as 
described in ES [71]. In most of the cases, the fusion gene interests EWSR1 and FLI1, 
located on chromosome 11 (Figure 2). In particular, genes breakpoints most commonly 
interest exon 7 of EWSR1 and exon 6 of FLI1 (type 1 fusion), showing a lower 
transactivation potential than a second variant interesting EWSR1 exon 7 and FLI1 exon 
5 (type 1 fusion). This lower transactivation potential appears to correlate with a higher 
relapse-free survival of ES patients [72]. The resulting fusion protein holds 264 amino 
acids of EWSR1 and 233 amino acids of the C-terminus portion of FLI1.      
      
                          
Figure 2. Representation of EWS-FLI1 chimera resulting from            
t(11;22)(q24;q12) translocation [73].   
 
Breakpoints can occur in different sites of the genes and result in several isoforms of the 
chimera: variations interest 264-348 amino acids of EWS and 191-324 amino acids of 
FLI1. EWS-ETS fusion proteins act as aberrant transcription factors modulating the 
expression of target genes in a sequence-specific manner that is determined by the ETS 
component under the control of potent EWS transactivation component [49]. In vitro 
studies demonstrated that forced EWS-FLI1 expression is transforming in NIH3T3 
murine fibroblasts while its silencing, via antisense RNA or short interfering RNA 
(siRNA), caused growth inhibition, apoptosis, decreased anchorage-independent growth 
and tumorigenicity in vivo [74-79]. By contrast, EWS-FLI1 expression in mouse 
embryonic fibroblasts or human primary fibroblasts failed to induce transformation and 
resulted in growth arrest and apoptosis [80, 81]. These last results underlie the 
importance of a specific cellular context for EWS-FLI1-mediated oncogenesis [73]. 
Beside not so extensively studied, all the EWS-ETS fusion proteins act as aberrant 
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transcription factors and induce the same transformed phenotype. Beside other EWS-
ETS rearrangements have not been so extensively studied, evidences suggest that all 
EWS-ETS proteins act as aberrant transcription factors that can regulate gene 
transcription and transform cells [72]. Explanation of this common behavior could be 
the loose specificity of ETS proteins for target genes [82] and the contemporary high 
homology in the DNA-binding domain [72]. Nevertheless, some functional differences 
have been observed between the various translocations: oncogenic transformation in 
NIH3T3 cells could be induced by EWS-FLI1, EWS-ERG and EWS-FEV but not by 
EWS-ETV1 and EWS-ETV4 [83]. Another difference regards the location of the tumor 
as in one study 11 cases on 12 harboring EWS-FEV, EWS-ETV1 or EWS-ETV4 
presented extraosseous tumors but explanations are unknown. Overall, further studies 
are needed to better understand these differences. In addition, non-EWS fusions have 
been identified in less than 1% of cases. TET proteins family includes EWS, TLS and 
TAF15 and TLS/ERG or TLS/FEV have been described in some  ES patients adding 
complexity to the ES biology. It is generally assumed that TET-ETS proteins function 
in a similar fashion compared to EWS-FLI1 but further studies will be necessary [70]. 
As oncogenic processes are due to the aberrant transcriptional activity of the chimera, 
several studies have been performed to identify EWS-ETS target genes. From this point 
of view, RNA-interference (RNAi) based approaches, microarray technology and ChIP 
analyses have been useful tool to identify a large number of genes dysregulated by 
EWS-FLI1. Studies have demonstrated that NR0B1, NKX2.2, GLI1 are up-regulated by 
EWS-FLI1 and possess a critical relevance in oncogenic transformation.  On the other 
side, EWS-FLI1 deregulates genes involved in cell proliferation, evasion of apoptosis, 
drug-resistance, cell cycle control, angiogenesis. Particularly, the chimera up-regulates 
PDGFC, IGF-1, MYC, CCND-1 e NKX2.2 while down-regulates p21, p57, TGFβRII 
and IGFBP3 [70]. Some studies suggest that EWS-FLI1 oncogenic activity may also be 
mediated by some DNA-binding-independent mechanisms. Indeed, expression of EWS-
FLI1 molecules with point mutations or large deletions in the ETS in NH3T3 cells were 
still able to induce tumors in mice [84].  
Additional chromosomal changes that are frequently found in ES include gain of 
chromosome 1q (32%) and chromosome 2 (29%), trisomy of chromosomes 8 (67%), 
and 12 (29%), losses of 9p (23%) and 16q (32%) [85, 86]. In addition, patients with 
primary tumor with low copy number changes (≤ 3 copy number aberrations) show a 
significant better prognosis in terms of overall and event-free survival respect to those 
with a high number of alterations [86]. Homozygous deletions of CDKN2A, encoding 
p16
INK4a
, has been observed in 10 to 30% of the cases and is associated with poor 
prognosis when combined with co-presence of mutations on p53 [87]. Inactivating point 
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mutations of TP53 are present in 4-14% of cases and are associated with poor outcome 
when compared to patients with wild type p53, defining another subgroup of patients 
with poor clinical outcome [88]. Recently, as performed in other tumor types, the 
genomic landscape of ES has been explored with next generation sequencing techniques 
in order to identify additional molecular alterations that could be associated with tumor 
aggressiveness. The results demonstrate that ES genome is very stable with a low 
somatic mutational rate, compared to other tumors. Indeed, results from three different 
groups highlighted just one genetic mutation more together with those previously 
described. In particular, they discovered inactivating mutations on cohesin complex 
subunit STAG2 in 21.5% of tumors [89-91] and STAG2 mutations were found 
associated with poor overall survival [91]. This low mutational rate could be due to the 
short amount of time of pediatric cancers to accumulate passenger mutations or to a 
preponderant epigenetic- more than genetic-driven oncogenesis in pediatric tumors. In 
addition, this could be a specific feature of fusion-driven cancers [89]. From the clinical 
point of view, this paucity of mutations represents a limitation for the identification of 
targetable pathways [90]. Overall, the results further highlight the importance of EWS-
ETS rearrangements in this tumor type. As previously mentioned, EWS-FLI1 requires a 
specific cellular environment to induce oncogenic transformation. Some critical factors 
that have been identified include the presence of an intact insulin-like growth factors 
(IGF) system and the expression of CD99, a 32kDa integral membrane glycoprotein 
expressed in 90% of the cases. EWS-FLI1 directly affects at transcriptional level the 
expression of important components of the IGF system thus creating the loop IGF-
1/IGF-1R sustaining cell growth [92]. CD99 acts as an oncogene in ES cells as 
triggering of this molecules induces apoptosis and inhibition of growth in vitro and in 
vivo and prevents normal neural differentiation [93, 94]. Considering its high 
expression, it is considered a diagnostic biomarker together with neuron-specific 
enolase (NSE), S-100, synaptophysin and, depending on the level of neural 
differentiation, vimentin, cytokeratin and neurofilament [73]. 
 
 
 
2.7  Treatment  
 
ES treatment is based on a combination of  chemotherapy,  surgery, and radiotherapy 
[95]. The standard approach is given by local treatment of the tumor (surgery and/or 
radiotherapy) and cycles of systemic chemotherapy (pre- and postoperatively). Surgery 
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plays an essential role in treatment of primary tumor, especially to avoid radiotherapy, 
but it is not always feasible. Conventionally, in case of localized disease neo-adjuvant 
chemotherapy is applied for a local control and to facilitate surgery. Chemotherapy 
response is than monitored to evaluate clinical response and modulate adjuvant 
chemotherapy. Chemotherapy is used as a combination of six drugs: cyclophosphamide, 
ifosfamide, adriamycin, vincristine, dactinomycin D, and etoposide. Multicentric 
clinical studies demonstrated an higher efficacy for the association of 4 drugs including 
cyclophosphamide, adriamycin, vincristine, and dactinomycin D more than an 
association of 3 drugs or the single drugs alone. Patients with metastatic disease remain 
a therapeutic challenge. Patients with metastasis at diagnosis show a worse prognosis 
when treated with the same regimen utilized for localized disease. For these patients a 
more aggressive treatment is necessary and consists of higher doses and a reduced time 
between cycles of treatment followed by myeloablative therapy and stem-cells 
transplantation [56]. Overall, such aggressive treatment causes severe side effects. 
Therapy amelioration represents an urgent need for ES and particularly for patients with 
metastatic disease. Unfortunately, few new drugs are available for ES treatment and 
always are less effective than conventional drugs. Innovative therapeutics have been 
developed based on biological features of ES cells. In ES, IGF-1R represents an 
attractive target of both monoclonal antibodies (MAb), including AVE1642, CP-
751,871, IMC-A12, and tyrosine kinase (TKI) inhibitors, including AEW-541 and 
ADW742. These agents showed good preclinical results  but poor clinical effects with 
just a 10% of patients experiencing relevant benefits [96] especially for mechanisms of 
innate or acquired resistance. Considering its elevated expression in ES cells and its key 
role in ES malignancy, CD99 molecule has been considered as potential therapeutic 
target. Recently, a new anti-CD99 MAb scFvC7 has been described showing benefits 
based on its specificity to ES cells. Trabectedin, ET-743, is an alkylator agent with 
antitumoral activity in different tumors, particularly those bearing translocations. In 
myxoid liposarcoma, Trabectedin down-regulates the binding of FUS-CHOP fusion 
gene product to promoter regions of its target genes. Some studies demonstrated that, 
similarly, Trabectedin interfers with EWS-FLI1 activity [97]. In ES, clinical trials have 
been performed showing an insufficient activity of this agent as monotherapy but a 
good tolerability with low side effects [98, 99]. 
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3. Prostate cancer 
 
3.1  Epidemiology and risk 
 
The first case of prostate cancer (PCa) was diagnosed by histological examination in 
1853 by J. Adams, a surgeon at The London Hospital, who described this condition as 
“a very rare disease” [100]. Today, PCa is the second most diagnosed cancer in adult 
men and the sixth cause of death in males accounting for 14% of new cancer cases and 
6% of cancer death worldwide. Incidence of PCa is 2 to 5 times higher in developed 
countries compared with developing countries as a result of a set of risk factors and 
diagnostic procedures [101]. Several risk factors have been identified during the years 
and, despite no preventable factors exist, a general knowledge about them should be 
maintained. Advanced age is the principle cause of PCa as most of the cases are men 
over the age of 65 while it is rarely seen in men younger than 40 years. Autopsy data 
indicate a 90% of prevalence in men ages 70 to 90 indicating more men will die with 
PCa more that for it [102]. The second most common risk factor is the race with the 
highest risk in Africans, intermediate in Caucasians and lowest among Asians [103]. 
The role of ethnicity is still unclear but may be related with a combination of 
socioeconomic, environmental and dietary factors. Family history of PCa is a third well 
established risk factor for the disease [104]. Particularly, the risk of PCa is two times 
increased in men with a first degree relative and is even higher if the relative was 
diagnosed at an age younger than 60 [105].  
 
3.2  Prostate anatomy and histology 
 
In men, prostate is a partly glandular and muscular organ surrounding the urethra at the 
base of the bladder. Together with seminal vesicles and bulbourethral glands, prostate 
represents an accessory gland of reproduction as its primary function is to secrete an 
alkaline fluid forming part of the ejaculate, which aids in motility and nourishment of 
the sperm. This fluid (pH 7.29) is rich in lipids, proteolytic enzymes, acid phosphatase, 
fibrolysin and citric acids. The smooth muscle part of prostate helps semen expulsion 
during ejaculation. The prostate gland is surrounded by the prostatic capsule and 
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neurovascular bundles outside of the capsule are responsible for erectile function. 
According to the classic work of McNeal [106-108] , the prostate gland is characterized 
by three major glandular regions: central, transition and peripheral zones (Figure 3). A 
fourth zone is an anterior fibro-muscular zone lacking glandular components as it is 
composed of muscle ad fibrous tissue. The central zone refers a vertical wedge of 
glandular tissue lateral to each ejaculatory duct. A narrow band of stroma separates the 
central zone from peripheral zone. Transition zone was found to lie in the convexity of 
the peripheral zone. Differences between the three areas were described in terms of 
stroma and glandular architecture. At histological level, prostate contains a 
pseudostratified epithelium with three differentiated epithelial cell types: luminal, basal 
and neuroendocrine [109-111]. Luminal cells form a continuous layer of polarized 
columnar cells that produce protein secretions and express markers including 
cytokeratins 8 and 18 and high levels of androgen receptor (AR). Basal cells are located 
under the luminal cells and express p63, cytokeratins 5 and 14 but low or undetectable 
levels of AR. Neuroendocrine cells are rare cells, which function is unknown, 
expressing endocrine markers but no AR. In 75% of cases, PCa develops in the 
peripheral zone while benign prostatic hyperplasia (BPH) develops in the transition 
zone [112]. 
 
 
Figure 3. Sagittal 
diagram of adult human 
prostate showing distal 
urethra (UD), proximal 
urethra (UP) and 
ejaculatory duct (E). 
Three major glandular 
zones are shown: central 
zone (CZ), peripheral 
zone (PZ) and transition 
zone (TZ) [113]. 
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3.3  Diagnosis and staging 
 
From a clinical point of view, patients with PCa at early stages are mostly 
asymptomatic. Lower urinary tract symptoms including weak stream, urgency, 
frequency, nocturia, incomplete emptying and incontinence may be present but are 
common with benign prostatic hyperplasia. Patients with PCa may also present 
hematuria, hematospermia and erectile dysfunction. Urinary symptoms must be 
accompanied by further analysis in order to distinguish PCa from inflammatory 
disorders or hyperplasia. In advanced disease, patients may present bone pain in 
different locations including hips, back and pelvis, or unexplained anemia [114]. In 
95%, PCa refers to an adenocarcinoma, originating from prostate gland epithelial cells 
in peripheral zone and with luminal phenotype. However, other categories of PCa exist 
such as ductal adenocarcinoma, mucinous adenocarcinoma and neuroendocrine prostate 
cancer but are extremely rare [115]. Diagnosis of PCa is performed by a histologic 
evaluation of prostate tissue sampled from a prostate needle biopsy. However, the 
decision to perform a biopsy depends on prior Prostate Specific Antigen (PSA) 
evaluation and digital rectal examination (DRE) findings as well as on age, ethnicity 
and co-morbidities. PSA is a serine protease of the Kallikrein family produced by the 
prostate and a component of seminal fluid important for ejaculation. Serum evaluation 
of PSA for early PCa detection is part of the clinical practice since the 1980s [116]. 
Normal PSA value ranges from 0 to 4 ng/ml while it is found increased in case of PCa 
as well as BPH, infections, ejaculation within 48 hours of serum evaluation, trauma and 
age. For this reason, PSA serum evaluation remains an imperfect test. Nevertheless, 
prostate biopsy is recommended for men with a serum PSA ≥ 4.0 ng/ml regardless of 
DRE [117]. DRE is limited because it allows palpation of the posterior surface of the 
gland but it is performed regardless of PSA analysis results. Men with positive DRE are 
directed toward a biopsy independently on PSA serum levels. Considering the 
limitations of both PSA evaluation and DRE, research of new biomarkers for early 
diagnosis of PCa with characteristics of high specificity and sensitivity represent an 
urgent need for this tumor. Transrectal ultrasound-guided needle biopsy represents the 
main method to obtain prostatic tissue. The number of biopsies rage from 8 to 16 and 
most of the tissue is sampled from the peripheral zone. The most common 
complications of this procedure are hemorrhagic including hematuria, hematospermia 
and hematochezia [118] thus patients taking antiplatelet drugs should discontinue the 
treatment. Prostate biopsy is then categorized by the pathologists using a grading system 
known as the Gleason Scoring system. This system was described in the 1960s and it 
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characterizes prostate tumor architecture and morphology. In addition, Gleason score 
represents the strongest clinical predictor of PCa progression [119]. The Gleason system 
assigns a grade to the two largest areas in each biopsy specimen. Grades span from 1 to 
5 where 1 is the least aggressive and 5 is the most aggressive. The two numbers are 
added and men diagnosed with a Gleason grade 7 or more are at increased risk of 
extraprostatic extension, recurrence after initial therapy and more likely to die for the 
disease. On the opposite side, men with Gleason minor that 7 have a low risk of cancer-
specific death. In a study published in 2011 from Eggener et al. the overall 15-year PCa 
specific mortality rate was evaluated in a cohort of more than 10000 patients treated 
with radical prostatectomy. The results showed that the probability of death from PCa 
varied by the age of the patients ranging from 0.6-1.2% for Gleason 6 or less, 4.7-6.5% 
for Gleason 3+4, 6.6-11% for Gleason 4+3, and 22-37% for Gleason 8 or higher [120]. 
The staging of PCa is determined by PSA value, DRE findings, prostate biopsy results, 
and Gleason score and it is important to establish the treatment options for the patients. 
Staging is divided between clinical and pathological: clinical staging is based on clinical 
findings such as PSA, DRE and imaging while pathologic staging is based on tissue 
diagnosis and relies on the TNM system developed by the American Joint Committee 
on Cancer. The TNM system describes the extent of tumor (T), lymph node 
involvement (N), and presence of metastatic disease (M). Each category is further 
divided in subcategories. Extent of the tumor is divided into T1-T4 with higher T 
indicating higher involvement of the prostate and surrounding structures. Node category 
is divided in 0 or 1 indicating lymph node involvement. Metastatic disease is 
categorized in 0 if the disease is not spread or 1. Considering all these parameters, 
patients are classified as “low-“, “intermediate-“ or “high-“ risk.       
 
3.4  History of prostate cancer 
             
Heterogeneity and multifocality represent two main characteristics of PCa posing 
significant difficulties both at clinical and research level. Histological inspection of PCa 
tissue reveals the high heterogeneity of this tumor type as it is characterized by 
juxtaposition of benign glands, preneoplastic foci, and neoplastic foci of varying 
severity [115]. Regarding multifocality, it has been widely described that, within a 
section of PCa, individual genetically distinct neoplastic lesions, even in close 
proximity, can be present. This evidence suggests multiple neoplastic foci may emerge 
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and evolve independently [121]. The main mediator of PCa development, as well as 
normal prostate, is the AR. Particularly, AR sustains the proliferation of tumor cells 
with its transcriptional activity upon stimulation of androgens. The most abundant 
androgen is testosterone that is activated by 5a-reductase in dihydrotestosterone. In PCa, 
AR suppresses proliferation of basal cells, supports survival of luminal cells and 
promotes metastasis as demonstrated by studies in mice [122].  
 
 
3.4.1 Cell of origin 
Several studies have been conducted in mice to determine the cell of origin of PCa.  
Considering the luminal phenotype of human PCa, the cell of origin should correspond 
to either a luminal cell [123, 124] or a basal cell that can differentiate into luminal 
progeny following oncogenic transformation [125].  Particularly, studies of PSA-Cre; 
Pten
flox-flox
 mice suggested a luminal population corresponding to the cell of origin in 
this model [126]. Analysis of Probasin-Myc and Nkx3.1-Myc transgenic mouse lines 
suggested the same luminal origin [127]. In addition, histopathological evidence of 
MYC expression in preneoplastic lesion is in line with the luminal origin of this tumor 
as MYC is exclusively expressed by luminal cells but not basal cells [128]; similar 
results have been reported with respect to telomere shortening [129] and the androgen 
related-TMPRSS2-ERG fusion gene as AR is expressed by luminal cells [130]. On the 
opposite side, different studies reported strong evidences regarding the basal origin of 
this tumor. In the paper from Goldstein et al. it is demonstrated that injection of the 
mixture of urogenital sinus mesenchyme (UGSM) with human prostate basal or luminal 
cells into immunodeficient NOD(-)SCID(-)IL(-)2Rg-/- mice induced adenocarcinoma 
when using basal cells but not luminal [125]. Another study conducted in Pb-Cre4; 
Pten
flox/flox
 mice showed an expansion of basal cells as well as intermediate cells 
coexpressing basal and luminal markers in tumors [131]. More recently, an analysis of 
basal and luminal epithelial populations from mouse prostate has shown that basal cells 
are more readily transformed by lentiviral expression of ERG and AR in tissue 
reconstitution experiments [132]. Overall, these data indicate that despite all the 
information obtained until now, further studies are necessary to better elucidate the 
origin of this tumor. It remains unclear, whether different cells of origin are used in PCa 
initiation [123].   
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3.4.2 Prostatic intraepithelial neoplasia (PIN) 
 
PIN is a specific type of lesion that is believed to represent the primary precursor of 
human PCa beside this relationship has not been demonstrated conclusively [133]. At 
histological level PIN is characterized by the appearance of luminal epithelial 
hyperplasia, reduction in basal cells, enlargement of nuclei and nucleoli, cytoplasmic 
hyperchromasia, and nuclear atypia and increased expression of cellular proliferation 
markers, in case of high-grade PIN [123] (Figure 4).  PIN can be found as low-grade or 
high-grade forms with high-grade form thought to represent the precursor of early 
invasive carcinoma as demonstrated by different evidences. PIN lesions are found in 
peripheral zone [134] and the features of high-grade PIN lesions generally precedes 
those of carcinoma by at least 10 year, according with the idea of cancer progression 
[135]. In addition, PIN lesions are multifocal as demonstrated by allelic imbalance 
analysis and chromosomal abnormalities found in PIN are similar to those of early 
invasive carcinoma [136, 137]. Architectural and cytological features look like those of 
invasive carcinoma including disruption of basal layer [138]. Eventually, PIN lesions 
express markers of differentiation commonly altered in early invasive carcinoma 
including E-cadherin and vimentin [139, 140]. On the opposite side, exclusive PIN 
characteristics include intact basement membrane [138], no PSA expression [140], 
similarity between PIN histological characteristics and premalignant lesions of the 
breast [141]. In addition, PIN lesions show architectural and cytological characteristics 
that are not believed to be precursor features of prostate cancer [123].  
 
 
 
 
Figure 4. Histopathology of human PCa. Hematoxylin-eosin-stained section of human (A) 
benign normal tissue, (B) PIN, (C) well-differentiated adenocarcinoma, (D) poorly-
differentiated adenocarcinoma [123]. 
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3.4.3 Latent and clinical cancer 
Prostate carcinogenesis is a process of 20-30 years or more starting as a proliferative 
inflammatory atrophy (PIA), passing through PIN and in some cases leading in a 
carcinoma. Evidences suggest that one of the cause predisposing to cancer development 
could be a prostate inflammation due to infectious agents or ingestion of carcinogens. In 
addition, an inherited genetic background could also make an individual more 
susceptible to prostate tumorigenesis but implicated genes must be discovered yet [142]. 
Clinically, PCa can be divided in two main groups: prostate tumors able to spread that 
will end up being lethal with a clinical relevance, and others indicated as latent that are 
relatively indolent [143]. Autopsy studies have indeed demonstrated that almost 70% of 
men have a tumor in the prostate at the time of the death but with no clinical relevance. 
It has been estimated that 15-30% of males over the age of 50 and 80% of males over 80 
years of age harbor microscopic, latent PCa [144]. In addition, it is fatal for only 3% of 
men. From this point of view, PSA evaluation doesn’t represent an useful biomarker as 
it is informative of an organ- but not a disease-specific affection and PSA does not 
distinguish which type of PCa a man may have i.e. a cancer that will never cause a 
problem, a clinically relevant tumor that will cause morbidity and mortality if left in 
place or an incurable, metastasizing form [142]. Nowadays, the main challenges in the 
field of PCa research include the discrimination of the two forms of the disease, latent 
or clinically relevant, and consequently the identification of which men can be cured 
with treatment and which not require treatment avoiding treatment-induced morbidities.  
 
 
3.4.4 Metastasis 
 
The primary site for PCa metastasis is invariably the bone, where characteristics 
osteoblastic lesions are formed [145]. Secondary sites are represented by lung, liver and 
pleura [146]. Metastatic disease accounts for more than 90% of deaths associated with 
PCa and almost 90% of patients dead for PCa die of metastatic bone disease [147]. Most 
of bone metastasis are classified as osteoblastic, based on the radiographic appearance 
of the lesions indicating a deregulation of bone resorption and formation processes. 
Bone metastasis occur when PCa single cells, with acquired characteristics of motility 
and invasiveness, detach from epithelial sheet, reach the circulation, adhere to bone 
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marrow endothelial cells and migrate to the bone [148]. In patient, bone metastatic 
lesions cause severe bone pain, skeletal fracture, hypercalcemia, and spinal-cord 
compression [149]. Mechanisms by which PCa cells form preferentially bone metastasis 
and particularly osteoblastic skeletal lesions are overall unclear but numerous studies 
have been conducted. Firstly, according to Paget’s seed and soil theory [150], several 
bone paracrine factors contribute to the tropism of circulating PCa cells to the bone 
mediating the interaction between disseminated cells and resident bone cells [148]. 
From this point of view, this process involves a variety of adhesion molecules expressed 
by endothelial cells and PCa cells including CXCR4 [151], cadherin 11 [152], monocyte 
chemotactic protein-1 (MCP-1) and its receptor CCR2 [153]. Secondly, osteoblastic 
lesion is the result of the release of factors that stimulate osteoblast proliferation, 
differentiation and consequently uncontrolled bone formation by metastatic cancer cells 
[154]. This last process is also due to the osteo-mimicry capability of tumor cells. It is 
still to be clarify whether cancer cells already possess osteomimetic phenotype or it is 
acquired in the bone marrow. Anyhow, PCa cells are able to express factors involved in 
normal bone development and remodeling. Osteoblastic differentiation is a complex 
process regulated by several factors including bone morphogenetic proteins (BMPs), 
insulin-like growth factor (IGF)-1 and -2, transforming growth factor-β1 (TGFβ1) and  
TGFβ2, fibroblast growth factor (FGF), the transcription factor RUNX2 [148]. 
Interestingly, the same pathways are implicated in the activation of resident bone and 
bone marrow cells induced by PCa cells [155-157].  
 
 
3.5  Molecular biology of prostate cancer  
PCa progression is accompanied by genetic alterations and molecular pathways holding 
a specific significance in each stage. Emergence of large-scale sequencing studies of 
cancer genomes has allowed the identification of the elevated molecular heterogeneity 
of tumors including PCa [158]. Extensive genomic analysis in PCa have been 
performed and both copy number variations and translocations have been identified as 
the most common genetic alterations. One information that is still lacking is whether 
there is a temporal sequence associated with this events or they are casually related 
[123]. Mutations of AR represent one well-established alteration in this disease and they 
are mostly related with castration-resistant stage. AR is amplified in one third of the 
cases while 10-30% of tumors present gain-of-functions mutations. Recently, alternative 
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splice isoforms encoding constitutive active AR variants have been identified in 
castration-resistant tumors. In addition, some studies identified the endogenous 
expression of androgen synthetic enzymes in tumor tissue as a mechanism to activate 
AR [123]. Around 85% of PIN lesions and adenocarcinomas display loss-of-
heterozigosity (LOH) of chromosome 8p21.2 causing the deletion of a region containing 
the NKX3.1 homeobox gene [159]. NKX3.1 is an oncosuppressor gene with a relevant 
role in prostate epithelial cells differentiation [160]. Accordingly, NKX3.1 expression 
was found low expressed in series of PCa and metastasis or completely lost in advanced 
cancers [161]. Studies conducted in mice with the purpose to elucidate the role of 
NKX3.1 in cancer initiation evidenced that NKX3.1 inactivation causes a defective 
response to oxidative damage while its expression in PCa cell line protects against DNA 
damage [162, 163]. MYC oncogene has been found amplified in a subset of advanced 
PCa [164] while other studies found an up-regulation of MYC in PIN lesions and 
carcinomas in absence of gene amplification suggesting an altered regulation of MYC 
[128, 165]. MYC overexpression in mice induces PIN lesions, carcinoma and metastasis 
[166] and expression of MYC is sufficient to immortalize human prostate non-
tumorigenic cells [123]. In 2005, the group of Tomlins et al. described chromosomal 
rearrangements involving the androgen-responsive promoter of TMPRSS2, on 
chromosome 21, and one of the ETS transcription factor family gene. The most 
common of these rearrangements involves ERG, located on chromosome 21, and results 
in the TMPRSS2-ERG fusion gene. This rearrangement, which can be due both to 
deletion or translocation, causes an androgen-related over expression of transcription 
factor ERG. A small percentage of cases contains fusions with other ETS transcription 
factors as well as with promoter fusion partners other than TMPRSS2. Fusion genes 
have been identified involving ETV1 and ETV4 ETS genes while TMPRSS2 was found 
replaced by untranslated regions from the prostate-specific androgen-induced gene 
SLC45A3 [167]. TMPRSS2-ERG is expressed in 15% of PIN lesions and in 50 to 70% 
of localized PCa cases indicating it is an early event in this tumor [29]. Some evidences 
indicate that the formation of this rearrangement could be due to the androgen receptor 
activity itself that induces chromosomal proximity between the two genes following 
DNA damage [130]. Alternative splicing events of the initial fusion transcripts induce 
formation of more than eight fusion types which more frequently include the designated 
type III form involving TMPRSS2 exon 1 fused to ERG exon 4 and the type VI 
interesting TMPRSS2 exon 2 fused with ERG exon 4 [35]. It has been demonstrated 
that cases expressing type VI isoform were more aggressive than those expressing type 
III [168]. Studies exploring the functional significance of truncated ERG protein are 
controversial but suggest that ETS activation promotes epithelial-mesenchymal 
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transition (EMT) and invasiveness [169-171]. Nevertheless, TMPRSS2-ERG has been 
reported as insufficient to induce a transformed phenotype but instead to cooperate with 
other mutations [172]. The product of the fusion gene in PCa is a constitutive 
expression of ERG with a consequent deregulation of transcriptional pattern of the cells 
expressing the fusion gene. ERG was found particularly up-regulated in peripheral zone 
compared to transitional zone and analysis of deregulated genes indicated that 
TMPRSS2-ERG-negative tissues were more similar to normal control, while 
TMPRSS2-ERG-positive tissues displayed distinct deregulation of transcription [173]. 
Several studies have been focused on identification of target genes trying to elucidate 
mechanisms mediating malignancy. ChIP analysis pointed out that PIM1 oncogene is a 
direct target of ERG and that the consequent overexpression of PIM1 modifies cyclin 
B1 levels in TMPRSS2-ERG-positive cells [174]. In vitro and in vivo studies evidenced 
that ERG binds osteopontin (OPN) promoter. OPN is an extracellular matrix 
glycophopshoprotein involved in the metastasis which is up-regulated by ERG [175]. 
Other target of TMPRSS2-ERG are represented by cysteine-rich secretory protein 3 
(CRISP3), CACNA1D, PLA1A [176] but studies in this field are ongoing.  
PTEN (phosphatase and tensin homolog deleted on chromosome ten) is a tumor 
suppressor gene frequently altered in cancer and its protein represents a key mediator of 
the oncogenic phosphoinositide 3 kinase (PI3K) pathway. A copy number loss of PTEN 
has been described in PCa and it is considered as an early event in prostate 
carcinogenesis [177] while PTEN loss in mice results in PIN or adenocarcinoma [178]. 
Loss of PTEN has been described to cooperate with other mutations including loss of 
NKX3.1, up-regulation of c-Myc, and TMPRSS2-ERG fusion. More recently, recurrent 
mutations with a role in PCa aggressiveness were found in SPOP, FOXA1 and MED12 
genes [179, 180]. Up-regulation of Akt/PI3K pathway has been described in PCa as a 
consequence of PTEN loss but also because of mutations interesting Akt1 [181] or the 
p110β isoform PI3K [182]. Deregulation of this pathway has been particularly 
associated with castration-resistant disease. In parallel, the MAPK signaling pathway, 
including ERK (p42/44) and RAS or RAF, has been frequently found activated in 
advanced disease [123]. Other alterations frequently found in PCa include deregulation 
of oncogenic tyrosine kinases like Her2 or SRC [183, 184], up-regulation of the EZH2 
gene, encoding for a histone lysine methyltransferase, which amplification has been 
associated with aggressive tumors [185, 186]. In addition, the role of microRNAs 
(miRNAs) in PCa has been widely investigated. In studies of miRNA expression 
profile, a pattern discriminating between indolent from aggressive disease was 
evidenced [187] as well as specific miRNAs were associated with castration-resistant 
PCa [188]. miRNAs have been evidenced as regulators of important gene in PCa such 
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as PTEN, which expression is negatively regulated by the cluster miR-106b-25, or 
EZH2 that is regulated by miR-101 [189]. In addition several miRNAs have been 
associated with androgen receptor signaling including miR-125b, miR-21, miR-141, 
others were found to be involved with cancer-related cell migration such as miR-141, 
miR-143, miR-145. In addition, a serie of miRNAs was found associated with 
metastasis: down-regulation of miR-16, miR-32a, miR-126*, miR-205, miR-146a was 
found associated with metastasis while an up-regulation was found for miR-301 and 
miR-125b [190]. Overall, data from molecular biology underlie the heterogeneity of this 
tumor type and evidence that PCa can be considered as a collection of cancers [191] 
characterized by sets of molecular alterations. The concept of molecular classification of 
PCa can be useful in the perspective of personalized medicine as well as of 
identification of subgroup of patients with different prognosis.   
 
3.6  Prognosis and treatment 
Potential prognostic factors have been investigated in PCa at clinical, pathological and 
molecular level. Identification of prognostic biomarkers represents one of the main 
challenges in PCa management especially to discriminate between indolent tumors, 
which can be controlled by active surveillance, and tumors with aggressive behavior 
requiring more radical treatment strategies. Patients are divided in risk groups predicting 
biochemical relapse free survival, indicating increase in serum PSA after treatment, or 
clinical relapse free survival [192]. The strongest clinical predictor of PCa is the 
Gleason score where patients with Gleason 7 or more show increased risk of recurrence 
or death after initial therapy. PSA levels at diagnosis is a standard risk factor for patients 
stratification. Increased PSA at diagnosis is associated with poor outcome after 
treatment [193]. Clinical, pathological and lymphnode pathological stages and margins 
positivity are also considered determinants of PCa poor prognosis [194]. Together with 
clinical parameters, many molecular and genetic factors have been investigated to better 
individualize risk prediction [193] in cohort of patients undergone radical prostatectomy 
or radiation therapy. First, numerous studies evaluated the association of TMPRSS2-
ERG and outcome of PCa patients obtaining controversial results. Recently, the study 
conducted by Hägglöf et al pointed out an increased risk for PCa specific death for 
patients expressing the fusion gene [195]. This data is not in accordance with previous 
results obtained in two different studies [194, 196]. Nevertheless, the study by Rubio-
Briones et al. pointed out that, beside without affecting prognosis, TMPRSS2-ERG 
status classifies patients into groups defined by different clinico-pathological prognostic 
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factors with PSA, Gleason and margin status as prognostic factors in patients expressing 
the fusion gene while clinical stage (cT), Gleason and margins displayed prognostic 
relevance in non-expressors [194].  Molecular markers of PCa prognosis include Ki67 
[197], loss of PTEN [198] or Akt mutations [199]. More recently, high speckle-type 
POZ protein (SPOP) gene expression was found statistically associated with favorable 
biochemical and clinical progression free survival [179] while elevated insulin-like 
growth factor 2 binding protein 3 (IGF2BP3) serum levels were found associated with 
poor prognosis [200]. In addition, miRNAs prognostic value was considered as well by 
several studies. Particularly, a recent study evidenced miR-187 and miR-182 as 
promising prognosis biomarkers in PCa [201]. Prognosis makers expression, extent of 
the disease and patient age support the clinician in the decision of the most appropriate 
treatment. Despite guidelines exist, the main purpose of all the efforts in the field of 
biomarkers research is to address the patient toward a personalized treatment. 
Consequently, patients will receive the most effective treatment with less side effect 
avoiding useless and expensive therapies. Therapeutic options are thus different 
considering, first of all, whether patient is affected by localized or advanced disease. In 
case of localized disease, the therapeutic options are radical prostatectomy, radiotherapy 
or cryotherapy. Surgical intervention for definitive treatment of PCa includes open 
radical prostatectomy, laparoscopic radical prostatectomy and robot-assisted 
laparoscopic radical prostatectomy. During the intervention the entire prostate gland and 
seminal vesicles are removed. Radical prostatectomy side effects are erectile 
dysfunction (ED) and urinary incontinence (UI). External beam radiation therapy (XRT) 
means to deliver a curative dose of radiation to the prostate without damaging 
surrounding tissues including bladder, rectum and bowel. Radiation therapy is a good 
option for patients who are poor surgical candidates and radiation regimens must be 
formulated based on risk levels. Side effects include urinary urgency and frequency, 
dysuria, diarrhea, proctitis. Brachytherapy involves placing radioactive sources into the 
prostatic tissues via needles, seeds, or wires under transrectal ultrasound guidance. 
Rates of brachytherapy can be high- or low-dose where the low-dose-rate consists of 
permanent implantation of  “seeds”, whereas high-dose-rate is temporary. This therapy 
is indicated for low-risk disease. Side effects are the same of XRT plus urinary 
retention. Cryotherapy is a surgical intervention involving freezing of the gland. A 
cryoprobe is inserted into the prostate through ultrasound guidance to a temperature of -
100° to -200° for 10 minutes. Localized high-risk disease where prostatectomy is not 
possible is indicated for this treatment. Complications include ED, UI, urinary retention, 
rectal pain, fistula. Advanced disease refers to recurrent PCa following therapy, locally 
recurrent disease, systemic recurrence, or clinical recurrence. Hormone therapy goal in 
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PCa is to reduce the levels of male hormones preventing the activation of AR and is 
indicated for patients with advanced non metastatic disease . Castration can be carried 
out surgically with orchiectomy or chemically with luteinizing hormone-releasing 
hormone (LHRH) agonists. LHRH agonists most commonly used are leuprolide, 
goserelin, triptorelin and histrelin and they can be used alone or in combination with 
nonsteroidal antiandrogen like flutamide, bicalutamide, nilutamide. Unfortunately, 
response to chemical castration lasts for 2 or 3 years before PSA begins to rise and in 
that case patients are considered to have hormone refractory disease. In case of 
refractory disease, secondary hormone therapy represents a therapeutic option. Overall, 
hormone therapy has a significant impact on quality life with both acute- and long-term 
effects. Acute side effects include fatigue, hot flashes, flare effects while long-terms 
effects include cardiovascular disease, anemia, osteoporosis, sexual dysfunction. 
Chemotherapy is used for the treatment of hormone refractory metastatic PCa and the 
standard of care is docetaxel-based regimen. Docetaxel is administered in combination 
with prednisone or mitoxantrone. Adverse side effects are myelosuppression, 
hypersensitivity reaction, gastrointestinal upset, peripheral neuropathy. Patients with 
bone metastasis should be considered for biphosphonate therapy with zoledronic acid. 
Emerging therapies for the treatment of hormone refractory metastatic PCa are 
cabazitaxel, abiraterone acetate, denosumab. Cabazitaxel is a microtubule inhibitor 
approved for patients who have already been treated with docetaxel. Adverse effects 
include neutropenia, gastrointestinal disturbance, renal insufficiency. Abiraterone 
acetate is a second-generation anti-androgen drug that blocks the synthesis of androgens 
through the inhibition of 17 α-hydroxylase/C17,20 lyase (CYP17A1). Denosumab is a 
monoclonal antibody targeting RANKL, a protein involved in bone destruction. Side 
effects indeed are hypocalcemia and osteonecrosi of the jaw [202].  
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4. The IGF system 
 
The insulin-like growth factor (IGF) system includes three ligands (IGF-1, IGF-2 and 
insulin), three receptors (IGF-1R, IGF-2R and insulin receptor - IR), and 6 IGF binding 
proteins forming a family of extracellular proteins that bind IGF-1 and IGF-2 thus 
regulating their bioavailability and activity [203, 204] (Figure 5). The IGF system plays 
a pivotal role in normal growth and development and it mediates several aspects of 
malignant phenotype in a variety of human malignancies [205].    
 
 
 
Figure 5. Schematic representation of IGF system [206]. 
 
 
4.1 The receptors 
 
The IGF system includes IGF-1R, IGF-2R, IR and hybrid receptors. IGF-1R and IR 
evolved from an ancestral gene and display an elevated homology rate: 45 to 65% in the 
ligand binding domains and 60 to 85% in the tyrosine kinase and substrate recruitment 
domains. Together the two receptors control metabolism, growth, differentiation and 
nutrient availability [207]. Beside the elevated homology, IGF-1R and IR carry out 
different functions inside the cell. Particularly, IGF-1R regulates cell proliferation while 
IR has a metabolic role. In vivo studies demonstrated that null mutants for IGF-1R 
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exhibit a severe growth deficiency (45% normal size) and die early for organ hypoplasia 
[208] while mice lacking IR display an almost normal size (80-90%) but die for severe 
hyperglycaemia and hyperketonaemia consistent with the preponderant metabolic 
actions of IR [209]. The IGF-2R or cation-dependent mannose-6-phosphate receptor 
does not share a phylogeny with IGF-1R and IR. It is considered an oncosuppressor as 
down-regulates IGF-2 modulating its availability. In addition, loss of IGF-2R induces 
an increase of body size in mice [210, 211].  
 
 
 
 
4.1.1  IGF-1R  
 
IGF-1R is a transmembrane tyrosine kinase receptor (RTK) constitutively expressed in 
most cells and tissues and which role is mediate long term actions on growth and 
development [212]. IGF1R gene, mapping to chromosome 15q25-26, comprises 21 
exons and spans more than 100 kb. Control of IGF-1R gene expression takes place both 
at transcriptional and post-transcriptional levels. Cloning studies pointed out that IGF-
1R promoter is regulated by cis- and trans-acting factors under physiological and 
pathological conditions. The promoter is highly GC-rich (around 80%) and lacks TATA 
and CCAAT boxes, normally required for efficient transcription initiation. Despite 
absence of these motifs, transcription of IGF-1R is initiated within a unique initiator 
element located around 1000 bp upstream of the ATG translation start codon [213].  
The gene codifies for a single 180 kDa chain and IGF-1R cDNA is composed of 4101 
nucleotides and predicts a  1367 amino acid precursor, including a 30 amino acid signal 
peptide which is removed during translocation of the polypeptide chain. The 1337 
amino acids left undergo a cleavage of the Arg-Lys-Arg-Arg sequence at position 707. 
The resulting propeptide is glycosylated, dimerized and translocated to the Golgi 
apparatus where it is cut by furin enzyme in α and β subunits [214]. Two αβ precursors 
are attached by disulfide bonds forming heterotetrameric IGF-1R complex (β-α-α-β) 
that is transported to the cytoplasmic membrane [215]. The N-terminal portion of IGF-
1R is glycosylated [216]. The mature IGF-1R is constituted by two α chains spanning 
130-135 kDa and two β  chains spanning 90-95 kDa, attached by disulfide bonds α-β, α-
α [217]. The two α subunits are completely extracellular and contain the ligand binding 
sites. IGF-1R binds IGF-1 and IGF-2, but not insulin, with high affinity. Studies based 
on the surface plasmon resonance technology demonstrated a difference of 4-fold in the 
IGF-1R affinity for IGF-1 compared to IGF-2 [218]. The two β subunits are composed 
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of an extracellular portion containing 5 glycosylated sites, a transmembrane 
hydrophobic region and the intracellular region holding domains involved in signal 
transduction: juxtamembrane domain, tyrosine-kinase domain (TK), ATP binding site 
and C-terminal portion [219].  
 
 
 
4.1.2 IR 
 
IR is expressed in liver, adipose tissue, skeletal muscle but also in brain, heart, kidney, 
pulmonary alveoli, pancreatic acini, placenta vascular endothelium, monocytes, 
granulocytes, erythrocytes, and fibroblasts [207]. This wide expression suggests that it 
is functionally involved in multiple mechanisms, in addition to the metabolic role. IR 
gene is located on chromosome 9 and it spans 120 kb containing 22 exons. The cDNA 
was isolated by the groups of Ullich and Rutter in 1985 and revealed two insulin 
receptor proreceptors sizes of 1343 and 1355 amino acids, respectively. This difference 
is due to the inclusion or not of a 12-amino acids segment at the C-terminal end of the 
IR α subunit. This segment is codified by exon 11, spanning 36 bp, that could be 
alternatively spliced [220]. As a consequence, IR exists as two isoforms: isoform A (IR-
A), lacking exon 11, and isoform B (IR-B) containing exon 11. As IGF-1R, IR is a 
heterotetrameric protein composed of two extracellular α subunits and two 
transmembrane β subunits attached by disulfide bonds. The α and β chains are 
synthesized by the same mRNA encoding for 1370 amino acids. The protein is cleaved 
by furin into α and β subunits, glycosylated and processed into the Golgi apparatus. α-
subunit contains 723 amino acids, with a molecular mass of 130 kDa while β-subunit is 
composed of 620 amino acids with a molecular mass of 95 kDa. Similarly to IGF-1R, 
the two subunits are involved in ligand binding and signal transduction, respectively. 
The two isoforms of IR display different binding affinity. Insulin is equally bound by 
IR-A and IR-B (EC50=0.2±0.2 nM e EC50=0.3±0.4 nM, respectively) [221]. A 
substantial difference regards the binding of IGF-2 where IR-A displays a higher 
affinity for IGF-2 compared to IR-B (EC50=0.9±0.4 nM e EC50=11.0±5.0 nM, 
respectively) [221]. None of the two isoforms is able to bind IGF-1 (EC50>30 nM) 
[222]. Exon 11 inclusion causes more differences between the two isoforms. IR-A is the 
predominant IR isoforms in fetal tissues where mediates mitogenic effects while IR-B 
appears in postnatal life in insulin-target tissues including liver, muscles, adipose tissue 
regulating glucose metabolism [223]. Recently, IR-A has been found up-regulated in 
different tumor types accordingly to studies performed on murine 32D cells indicating 
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that IR-A induces mitogenic and anti-apoptotic signals while IR-B induces 
differentiation stimuli [224]. Considering that IR-A is capable to bind both insulin and 
IGF-2, it has been demonstrated that the receptor induces mitogenic signals upon IGF-2 
binding while metabolic upon insulin binding [207]. 
 
 
  
4.1.3 Hybrid receptors 
 
In cells expressing both IGF-1R and IR, hybrid recptors (HRs) can be found as α-β IGF-
1R subunit can heterodimerize with one α-β of IR. In addition, IR isoforms can form 
heterodimers IR-A/IR-B. In this last case, it has been demonstrated that IR-A/IR-B 
hybrids recruit intracellular partners upon insulin or IGF-2 binding with the same 
affinity as IR-A homodimers while affinity for IGF-1 is low. The data suggest that, in 
presence of IR-A, IR-B hemireceptor is incorporated into hybrids with the consequence 
that most insulin binding sites behave as IGF-2 binding sites [207]. Heterodimerization 
occurring between IGF-1R and IR is mainly due to their high homology, spanning 27 to 
84% depending on the region [225, 226]. The amount of hybrids is function of the mole 
fractions of each receptor but in some tumor tissues the proportion of HRs is higher than 
the expected suggesting there are still more unknown factors that can influence homo- 
and heterodimers formation. HRs can involve IGF-1R/IR-A (HR-A) or IGF-1R/IR-B 
(HR-B) presenting different biological characteristics. Studies demonstrate that both 
HR-A and HR-B bind IGF-1 with elevated affinity (EC50= 0.3±0.2 nM and EC50= 
2.5±0.5 nM, respectively). Medium-high affinity occurs between insulin or IGF-2 and 
HR-A (EC50=3.7±0.9 and EC50=0.6±0.1, respectively) while they do not bind HR-B 
(EC50> 100 nM and EC50=15.0±0.9nM, respectively) [221]. In vitro studies exploring 
the HRs capabilities to phosphorylate a specific intracellular substrate, Crk-II, show that 
binding of the three ligands to HR-A determines Crk-II phosphorylation while IGF1 and 
IGF-2 only induce its phosphorylation upon HR-B binding. These results demonstrate 
that hybrids expression modifies insulin functional role as it induces mitogenic more 
than metabolic signals through HR-A activation. Modulation of insulin effects represent 
a main hypothesis regarding the physiological role of the HRs [207]. 
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4.2 Ligands and binding proteins      
 
IGF-1 and IGF-2 display a high homology with insulin structure and they control 
cellular and tissue growth [227]. IGF-1 is mainly produced by the liver under the 
control of the pituitary growth hormone (GH) but it can also be expressed by other 
organs with paracrine and autocrine effects [228]. For this reason, IGF-1 can be 
considered both a circulating hormone and a growth factor. IGF-1 gene is located on 
chromosome 12 and its expression is finely regulated in the liver. IGF-1 gene 
expression is induced by the GH, which production is regulated by the pituitary gland 
upon the regulation of the hypothalamic factors somatostatin and growth hormone-
releasing hormone (GHRH). With a feedback mechanism, IGF-1 inhibits GH release 
acting on hypothalamus and pituitary gland. The protein is a single chain of 7.5 kDa 
containing 70 amino acids. IGF-1 expression increases from birth to puberty, when 
stimulates growth and differentiation of different tissues including bone [229] while 
decreases in the adult. Similarly to IGF-1, IGF-2 is expressed by liver and other tissues 
in adults but its expression is not under GH control [230]. IGF-2 gene expression is 
controlled by genetic imprinting and it is expressed by paternal chromosome under the 
control of the differentially methylated region (DMR) associated with the H19 gene, 
located upstream on chromosome 11. When DMR is methylated IGF-2 is expressed 
[231]. Recently, a family of proteins called insulin-like growth factor 2 mRNA binding 
proteins (IGF2BP1, 2, 3) has been found able to bind IGF-2 mRNA thus affecting its 
expression. Particularly, binding of IGF2BP3 to IGF2 mRNA induces a stronger 
expression of the ligand with stimulatory proliferative effects in different tumor types 
[232]. At protein level, the two ligands share high homology (62%) but IGF-2 is 
composed of 67 amino acids and it is expressed during life and its plasmatic levels are 3 
to 7 folds higher that IGF-1. It induces proliferative and anti-apoptotic signals but it also 
plays a role in embryonic and fetal growth as well as in growth and differentiation of 
different tissues including muscle [233]. Insulin is a hormone produced by islets of 
Langerhans β cells in pancreas. Its active form is given by two chains: chain A, 
including 21 amino acids, and chain B, including 30 amino acids, cross linked by 
disulfide bonds. Insulin explicates mainly metabolic effects inducing glucose up-take of 
liver, adipose tissue and muscle upon hematic glucose increase. Specific amino acids 
confer to IGF-1 and IGF-2, but not insulin, the capability to bind a family of binding 
proteins (IGFBPs) which known components are 6. The IGFBPs hold IGF-dependent 
and –independent functions. In fact, they modulate half-life and bio-availability of 
IGFs: on one side they control  the IGFs translocation toward specific tissues (IGFBP-1, 
-2, -4) but they also sequester the ligands preventing the binding to the receptor: 
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IGFBP-6 binds IGF-2 with high affinity while IGFBP-3 binds preferentially IGF-1. 
IGF-independent mechanisms include the inhibitory effect of IGFBP-3 on cell 
proliferation and migration regardless of IGF-1 binding [234].    
  
 
4.3 IGF-1R: signal transduction pathways 
 
IGF-1R activation induces proliferative and anti-apoptotic stimuli to the cell. For this 
reason, IGF-1R effects are crucial for the correct embryonic and postnatal development 
in humans but are deleterious in the context of cancer as IGF-1R with its activity has 
been found involved in proliferation, survival, migration, metastasis and 
chemoresistance mechanisms in different tumor types. Upon the binding of IGF-1 and 
IGF-2, the kinase domain of IGF-1R is activated inducing the auto-transphosphorilation 
of three tyrosine residues in the TK domain (Tyr 1131, 1135, 1136). Consequently, the 
activated TK domain phosphorilates several IGF-1R residues and different intracellular 
substrates involved in signal transduction. In particular, phosphorilated tyrosine residue 
950 in the juxtamembrane domain serves as a docking site for IGF-1R substrates 
holding the Phosphotyrosine Binding Domain (PBT). The substrates include the family 
of insulin receptor substrates (IRS) 1-4 and Shc proteins [218]. These substrates initiate 
phosphorylation cascades that serve to transmit the IGF-1R signal.  
 
 
 
 
Figure 6. Representation of IGF-1R signal transduction [206]. 
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These proteins are recognized by down-stream effectors holding the Src-homology-2 
(SH2) domain such as PI-3K, Grb2/SOS, Ras GTPase activating protein [218].  
The phosphatidylinositol 3-kinase is composed of a p85 regulatory subunit and a p110 
catalitic subunit that, upon IRS-1 activation, phosphorilates phophatidylinositol-(4,5)-
biphosphate (PIP2) into phophatidylinositol-(3,4,5)-trisphosphate (PIP3). PIP3 activates 
down-stream substrates including protein kinase B (Akt) by phosphorilations on 
threonine 308 and serine 473. Akt phosphorilation, in turn, regulates metabolic enzymes 
such as glycogen synthase kinase 3 (GSK3), modulates apoptotic regulators like Bad 
and caspase 9, and activates the mammalian target of rapamycin (mTOR) pathway thus 
affecting protein synthesis through the p70 S6 kinase and the Elongation Factor 4 
binding protein-1 (4E-BP1).  
In parallel, IGF-1R leads to activation of Ras pathway. Ras is a GTP protein that is 
activated when binds GTP while inactivated when binds GDP [235]. Ras is recruited 
and activated by Grb2/SOS (ras guanine nucleotide exchange factor) complex: Grb2 is a 
docking protein that can be activated both by IRS-1 or Shc. The active form of Ras 
leads to activation of the serin/threonine kinase Raf1 and consequently MAPK (Mitogen 
Activate Protein Kinase) family components including MEK1 and ERK1/2. 
Translocation of ERK1/2 to the nucleus results in activation of a transcriptional program 
leading to cellular proliferation.  
In this way, IGF-1R controls different key points of cell cycle including the G0-G1, 
through p70S6 kinase activation determining ribosome synthesis and entrance into the 
cell cycle [236]; the G1-S progression is promoted by cyclin D1 increase and CDK4 
expression that, in turn, phosphorilates pRb thus inducing E2F release and cyclin E 
synthesis [237, 238]. Particularly, cyclin D1 control represents the main IGF-1R 
mechanism of cell cycle progression control: cyclin D1 synthesis is indeed mediated by 
both ERK1/2 and PI3K/Akt pathways. ERK1/2 regulates its transcriptional expression 
while PI3K/Akt pathway stabilizes cyclin D1 mRNA thus favoring its protein synthesis. 
In addition, IGF-1R regulates G2/M transition by promoting synthesis of cyclins A and 
B, and cdc2 [218]. IGF-1R also avoids apoptosis induced by different agents including 
hypoxia, osmotic stress and anti-tumor drugs [239]. Particularly, PI3K/Akt pathway 
induces inhibitory phosphorylation of pro-apoptotic factors, including Bcl-2 family 
member Bad [240], and caspase 9 [205]. Moreover, active Akt phosphorilates FoxO 
transcription factor family members regulating cellular functions including cell growth 
inhibition, and apoptosis induction through the anti-apoptotic protein Bim expression. 
Upon Akt-induced activation, FoxO proteins translocate to the cytoplasm where 
undergo ubiquitin-induced degradation. IGF-1R thus suppresses the FoxO proteins 
transcriptional program. The MAPK pathway-induced apoptosis inhibition is given by 
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ERK1/2-mediated activation of several substrates including c-Myc, a Bcl-2 repressor, 
and STAT3, inducer of anti-apoptotic proteins like Bcl-xL, Mcl-1, servivin.  
Depending on the cell type, IGF-1R can also directly phosphorylate the Janus kinases 
(JAK)-1 and -2 that are involved in cytokine-mediated signaling [218, 241]. 
Phosphorilation of JAK proteins can lead to activation/phopshorilation of STAT 
proteins. In particular, STAT3 represents a very important mediator of IGF-1R 
transforming potential [242]. 
 
 
4.4 IGF system and cancer 
 
The IGF system and, particularly, IGF-1R plays a critical role in various malignancies. 
Indeed, increased expression of IGF-1, IGF-2 and IGF-1R have been documented in 
different tumor types including glioblastomas, neuroblastomas, meningiomas, 
carcinomas of breast, gastrointestinal tract, ovarian, and Ewing sarcoma [218].  
IGF-1R involvement in neoplastic transformation was first demonstrated by Sell et al. 
Particularly, the authors conducted their study on fibroblast-like cell lines from mouse 
embryos homozygous for a targeted null mutation of the IGF1R gene. These cells 
showed refractoriness to semian virus 40 (SV40) large tumor antigen (TAg)-induced 
transformation compared to control cell lines, highly sensitive to SV40 transforming 
effects [243]. Several following studies demonstrated the resistance of this cellular 
model to the transformation induced by other viral and cellular oncogenes: active Ras, 
E5 protein from  bovine papilloma virus, E7 protein from human papilloma virus, EWS-
ETS fusion protein in Ewing sarcoma, viral oncogene v-src, over-expression of 
receptors like EGF-R, IR, PDGF-Rβ and IRS-1. In addition, restoration of IGF-1R 
expression made the cells susceptible to the transformation [244]. Conclusion of these 
data is that IGF-1R is necessary for cell transformation but not sufficient as it must 
cooperate with other agents (chemical, biological or phisical). In addition, the role of 
IGF-1R in cancer is not through its over-expression but through its presence [245]. IGF-
1R-mediated tumorigenesis can be due to genetic or functional alterations. 
Genetic alterations affecting IGF-1R include amplifications, and alterations of receptor 
regulators.  
IGF-1R gene amplification is a rare event but it has been described in melanoma [246], 
primitive breast cancer [247], pancreatic adenocarcinoma [248].  
Mostly, altered IGF-1R expression is induced by mutations of its transcriptional 
regulators. Transcription factors associated with IGF-1R control include both 
39 
 
stimulatory and inhibitory factors that have been identified in cancer. Inhibitory 
transcription factors include p53, WT1 and BRCA1. 
p53 is a nuclear transcription factor that is activated in response to DNA damage or 
hypoxia and it acts as an oncosuppressor as its activation leads to cell cycle blockade 
and apoptosis. p53 regulates gene expression of several components of the IGF system: 
it up-regulates IGFBP-3 [249] while down-regulates IGF-1R [250], IR [251], IGF-II 
[252] and IRS-3 [253]. p53 mutations, occurring in 50% of tumors, cause loss of 
IGFBP-3 and over-expression of IGF-1R, IGF-II, IR e IRS-3. In addition, loss of p53 
up-regulates IGF-1R through MDM2 recruitment and decreased IGF-1R ubiquitination. 
In turn, IGF-1R can regulate MDM2 expression and increase wild-type p53 
ubiquitination [254]. WT1 is an oncosoppressor that inhibits gene expression of IGF-1R 
and IGF-2.  
In Wilm’s tumor and in breast cancer, WT1 mutations or deletions cause IGF-1R and 
IGF-2 over-expression [250, 255].  More recently, several studies have demonstrated 
that IGF-1R undergoes nuclear translocation and it directly interacts with DNA. 
Moreover, IGF-1R binds IGF-1R gene promoter thus establishing an IGF-1R 
autoregulation mechanism as demonstrated in breast cancer cells thus sustaining its own 
expression [213, 256]. Studies in breast cancer demonstrated that IGF-1R is able to 
transactivate the IGF-1R promoter in ER-negative cells. It is still unknown if IGF-1R 
autoregulation is a general mechanism of gene regulation [256]. 
BRCA1 is a nuclear phosphoprotein with transcriptional activity and it is involved in 
regulation of the G1-S and G2-M transitions acting as an oncosuppressor [257]. In breast 
cancer, wild type BRCA1 represses IGF-1R transcription while truncated form of 
BRCA1 is unable to decrease IGF-1R promoter activity [258]. Consistently, BRCA1 
mutation carrier patients display higher IGF-1R levels than sporadic breast tumors 
[259]. Stimulatory transcription factors include EWS-WT1 chimera in desmoplastic 
small round cell tumor. This tumor is characterized by a chromosomal rearrangement 
involving EWS gene and WT1, on chromosome 11. The resulting chimeric protein 
possesses gain-of-function transcriptional activity and it was shown to bind WT1 cis-
elements and to transactivate the IGF-1R promoter [260].     
Functional alterations of IGF-1R refers alterations of IGFBPs, down-stream substrates, 
phosphateses regulating IGF-1R and its signaling, and IGF-2R.  
Tumor progression can be due to a reduced expression of IGFBPs that modulate IGFs 
availability both in circle and in tumor microenvironment. Decrease of IGFBP2 causes 
an elevated mitogenic capability as IGF-1 and 2 are available for the receptor binding. It 
has been demonstrated that proteases or caspases from tumor cells can digest the 
IGFBPs allowing ligand release [261]. Between the six IGFBPs, IGFBP-3 is the most 
40 
 
commonly lost in tumor cell lines [218]. An exception is given by IGFBP-2, which 
increased expression is associated with malignancy in glioma and other tumors [262, 
263].  
IGF-1R activity is altered by increased expression or constitutive activation of down-
stream effectors [218]. IRS-1 has been found constitutively activated in breast cancer, 
leiomiosarcoma, Wilms tumor, randomiosarcoma, liposarcoma [264] while IRS-2 is 
over-expressed in pancreatic tumor [265]  or consistutively phosphorilated in metastatic 
breast cancer compared to non metastatic cells [266]. In liver tumor, an up-regulation of 
IGF-II, IRS-1 and IRS-2 has been reported [267] as well as constitutive activation of 
ERK1/2 has been reported to reduce tumor IGFs- and IGF-1R-dependence  [268].  
Phosphateses regulating IGF-1R frequently altered in tumor include PTEN. PTEN 
attenuates the signaling of different tyrosine kinase receptors including IGF-1R as it de-
phosphorilates PIP3 thus blocking Akt activation. Loss of PTEN induces a constitutive 
activation of PI3K pathway and this mechanism has been described in different tumors 
such as prostate, lung, stomach cancers [269, 270]. Protein tyrosine phosphatase 1B 
(PTP-1B) is located in endoplasmic reticulum cytoplasm [271] and it exerts its action on 
IGF-1R and IRS-1 [272, 273]. Absence of PTP-1B causes increased proliferation, 
motility and growth [272].  
Internalization and ubiquitination mechanisms can alter IGF-1R functions. IGF-1R 
internalization is regulated by adaptor protein-2 (AP-2)-dependent endocytosis. Once in 
endosomal compartment, ligand dissociation exerts a regulatory role on signaling and 
some studies have pointed out the relevance of E-64-sensitive cysteine proteinase or 
cathepsin B. In addition, alterations on cathepsin L were observed in breast cancer cells 
[218, 274, 275]. IGF-1R ubiquitination is regulated by two E3 ligases: Nedd4 and 
mouse double minute 2 (MDM2). Nedd4 binds IGF-1R through the adaptor protein 
Grb10 and studies in mice have demonstrated that disruption in the maternal Grb10 
allele induces embryo and placental overgrowth and 30% overweight compared to wild-
type control [276]. MDM2 is a RING finger ubiquitin ligase that binds IGF-1R β-
subunit thus starting its degradation process. MDM2 loss causes an increase in IGF-1R 
expression levels [277]. 
IGF-2R represents an important oncosuppressor for the cell. It acts as a negative 
regulator of IGF-2 avoiding its binding to IGF-1R or IR. Different primitive tumors 
display loss-of-function mutations on IGF2R gene. In addition, studies conducted in 
prostate cancer cells showed that IGF-2R dominant negative expression causes 
increased cell growth rate while IGF-2R over-expression leads to growth decrease 
[278].  
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The role of IGF-1R in tumor pathogenesis and progression in widely accepted but its 
value as indicator of prognosis is still not completely clarify. Clinical studies evaluating 
the prognostic potential of IGF-1R have reported either positive or negative associations 
between receptor expression levels and patient outcome in different tumor types 
including prostate cancer [279], non-small cell lung cancer [280]. In breast cancer no 
correlation was found between IGF-1R and prognosis [281] while a correlation between 
higher IGF-1R expression and good outcome was found in primary Ewing sarcoma 
patients [282].   
In the last years, different studies evidenced that IR is abnormally expressed in a variety 
of tumor types where it mediates both metabolic and non-metabolic effects [207]. 
Particularly, studies demonstrated an altered splicing in tumor cells, leading to an 
increased ratio IR-A:IR-B that influences cell response to insulin and IGFs. IR-A is 
found over-expressed in carcinoma of breast, colon, lung but also rabdomiosarcoma, 
leiomiosarcoma, and miosarcoma. The relevance of IR-A expression is due to its 
capability to bind IGF-2. IGF-2 is frequently expressed by tumor cells and its binding to 
IR-A is associated with stimulation of growth and cell invasion [223]. IR-B is not able 
to bind IGF-2 and it is mainly associated with metabolic signals. Experimental studies 
demonstrate that IR-A over-expression in NIH 3T3 fibroblasts or immortalized human 
breast epithelial cells induces a ligand-dependent transformed phenotype and that this 
effect is blocked by IR-blocking antibodies [283]. However, these cells were not able to 
induce tumor in nude mice suggesting further alterations are required for a complete 
transformation. The importance of IR-A in tumor progression has been demonstrate in 
thyroid cancer where both IR and IGF-1R are over-expressed in differentiated tumor but 
IR-A:IGF-1R ratio progressively increases with the differentiation loss [284]. In 
addition, increased IR-A expression in tumor cells favors hybrids HR-A formation thus 
increasing IGF-1 and 2 binding sites and conferring growth advantage to the cells [221]. 
In addition, IR-A/IGF-2 circuit activation has been found able to mediate resistance 
mechanisms toward anti-IGF-1R agents [285] thus evidencing the relevant role of IR-A 
in tumor. 
The role of IGF-1 and IGF-2 in cancer is still controversial: a correlation between IGF-
1/IGF-2 expression levels and cancer progression has been evidenced in some tumor 
types including liver, colon-rectal, and pancreatic carcinomas but this was not 
confirmed in breast cancer. Overall, the data indicate a relevant role of the ligands in 
tumor progression [218]. In some tumor types this proliferative stimulus is given by 
circulating IGF-1 while in others by a paracrine or autocrine local synthesis of IGF-1 
and 2. Probably, tumors initially depend from ligands produced by the host while they 
become able to produce IGF-1 or IGF-2 autocrinely thus acquiring a higher malignancy 
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level during cancer progression. IGF-1 and IGF-2 circulating levels display a high 
variability among individuals especially because of polymorphisms of IGF-1 and IGF-2 
gene or alterations of ligand expression regulators including IGFBPs, GH and its 
receptor, somatostatina, GHRH and its receptor [261].  Epidemiological studies have 
evidenced that higher IGF-1 circulating levels are associated with increased cancer risk. 
Increased IGF-1 expression and polymorphisms of IGF-1 itself or its regulators has 
been correlated with increased risk of prostate, lung, breast, colon-rectal carcinomas and 
sarcoma [286]. Several studies have demonstrated a correlation between endogenous or 
exogenous insulin and cancer. In the 1970’s, studies in mice showed administration of 
exogenous insulin caused breast and colon tumors [287]. Animal models of insulin 
resistance, leading compensatory insulin increase, showed same results regarding 
endogenous insulin effects: insulin-resistance correlates with increased colon-rectal 
tumor formation in rats [288] and increased proliferation of lung and colon-rectal 
xenografts [289]. Epidemiological studies have demonstrated an increased risk of 
different tumors, including colon-rectal and endometrium cancer, in individuals with 
higher insulin levels [290]. Recently, type II diabetes and obesity have been 
demonstrated to be associated with increased risk of breast, colon, liver, pancreatic and 
kidney tumors [207]. These studies, together with the discovery of IR-A relevance in 
cancer, further support the hypothesis that insulin-resistance and the consequent 
hiperinsulinemia represent the main link between diabetes and cancer [291]. In an 
insulin-resistance condition, insulin-target tissues do not respond to insulin metabolic 
stimuli while other epithelial tissues undergo the mitogenic insulin stimulation [292]. In 
this condition, insulin can bind both IR-A and IGF-1R, with low affinity. In 
hyperinsulinemia condition, the MAPK pathway is preferentially activated and induces 
cell proliferation while the PI3K pathway, regulating metabolic signals, is normally 
inhibited [293].      
 
 
4.5 IGF-1R as a therapeutic target 
 
 
Development of targeted therapeutic strategies is based on the identification of specific 
alterations which are able to mediate cellular oncogenic pathways. In fact, the use of 
target therapies is indicated for those cancer where it is possible to identify a gene or a 
protein able to induce malignant phenotype. Identify a “druggable” substrate represents 
an exceptional chance for tumor treatment and an important option to improve patient 
outcome. Considering its biological effects, IGF-1R has emerged as a promising target 
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for the development of new therapeutic approaches, which can be combined with other 
classical chemotherapeutics [294]. In the past decades, several IGF-1R inhibitors, 
including monoclonal antibodies or tyrosine kinase inhibitors, have been developed and 
their efficacy has been tested in a large variety of tumor types. Overall, the data show 
that despite satisfactory preclinical effects, clinical trials did not give the expected 
results and this could be due to onset of resistance mechanisms or lack of a suitable 
patients selection. Identification of patients who can benefit of a specific target therapy 
represents today one of the main challenge in the field of cancer treatment. Agents 
aimed at IGF-1R down-regulation include monoclonal antibodies, tyrosine kinase 
inhibitors but also dominant-negative proteins, antisense oligonucleotides, RNA 
interference have been proposed.  
Several monoclonal antibodies have been developed to target IGF-1R. Monoclonal 
antobodies bind the extracellular domains of the receptor and block ligand binding. In 
addition, antibodies are able to induce IGF-1R down-regulation by promoting receptor 
internalization. The first available anti-IGF-1R antibody was αIR3. In 1989, Arteaga et 
al. demonstrated its efficacy as inhibitor of human breast cancer cells in athymic mice 
growth [295]. Some anti-IGF-1R antibodies are able to down-regulate IR, while being 
IGF-1R specific, due to down-regulation of IGF-1R:IR hybrids or to endocytosis of IR 
in close proximity to IGF-1R in membrane lipid drafts [296]. Fully human antibodies 
have been developed and tested in preclinical and clinical trials. Anti-IGF-1R 
monoclonal antibodies entered into clinical trials include CP-751,871 (figitumumab; 
Pfizer) and AVE1642 (ImmunoGen Inc. and Sanofi). CP-751,871 is a fully human IgG2 
blocking binding of IGF-1 to its receptor, IGF-1-induced receptor autophosphorylation 
and IGF-1R down-regulation [297, 298]. Its efficacy has been tested in phase I trials in 
different tumors including ES, prostate cancer, and multiple myeloma demonstrating to 
be well tolerated but with low effectiveness especially alone. AVE1642 is a humanized 
version of the anti-IGF-1R antibody EM164 [299]. Clinical trials have been performed 
to test its efficacy alone or in combination in a variety of solid tumors. Overall, data 
indicate again that the agent is well-tolerated but with partial responses especially in 
sarcomas [300]. Biomarkers for sensitivity to these agents remain an urgent need.  
Several compounds have been design to inhibit the tyrosine kinase activity of IGF-1R. 
From this point of view, complications are due to the high homology rate between IGF-
1R and IR particularly in the tyrosine kinase domain (85%) and the ATP binding cleft 
(100%). Small molecule inhibiting the kinase domain include NVP-AEW541 and NVP-
ADW742 (Novartis) appearing to be equipotent for IGF-1R and IR inhibition in vitro 
but specific for IGF-1R in intact cells [301, 302]. These agent displayed a good tumor 
growth inhibition in models of fibrosarcoma, myeloma, and ES but development of 
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these agents was let down by toxicity. Inhibitors of ATP binding cleft lack IGF-1R 
specificity while inhibitors of substrate phosphorilation show greater potential. In 
particular, the cyclolignan picropodophyllin showed a great specificity for IGF-1R as it 
inhibits tyrosine phosphorylation of Y1136 in the activation  loop of kinase domain. 
This agent showed a good potential in vitro. This class of compounds include OSI-906 
(Astellas Pharma), a novel ligand-dependent autophosphorylation inhibitor of both IGF-
1R and IR which show a good potential in those tumors expressing the two receptors. 
OSI-906 demonstrated good efficacy in preclinical studies and it is currently in clinical 
testing especially in combination with other drugs such as everolimus in colorectal 
cancer [303], doxorubicin in breast tumor cells [304]. In addition, biomarkers were 
found predicting response to OSI-906 in hepatocellular carcinoma cell lines [305]  or in 
colorectal cancer [306]. Several phase I and II clinical trials are ongoing.  
Dominant-negative proteins interfere with the wild-type protein by direct binding or 
competition for binding substrates. The first described dominant-negative is 486/STOP, 
holding an intact ligand-binding domain [307]. Its effects have been tested in 
experimental models of breast, pancreatic, lung, colon tumors where inhibits migration 
and metastases. Translation of this approach to clinical practice is limited by low 
efficiency of delivery and stability.  
Antisense oligonucleotides approach involves introduction into the cells of antisense 
RNA or antisense oligonucleotides  (ASOs) binding to a complementary mRNA target. 
Gene expression is inhibited by RNase H-mediated mRNA cleavage or translation 
block. Experimental studies demonstrated that antisense against IGF-1R cause growth 
inhibition and apoptosis induction in vivo. Use of oligoantisense in clinic is limited by 
low cellular up-take, non specific toxicity. Topical application or ex vivo transfection 
represent two putative options to overcome these limitations. In the last case, patients 
treated with ex vivo approaches display a clinical amelioration in 60% of cases [308] 
confirming the benefit of an anti-IGF-1R treatment.  
RNA interference technique known since 1998 as a process in which long double-
stranded RNAs  (dsRNAs) are cleaved by Dicer ribonuclease enzyme into short 21-23 
nuleotide fragments called short interfering RNAs (siRNAs). siRNAs are incorporated 
into a multi-protein RNA-inducing silencing complex (RISC) in which the antisense 
siRNA target the cleavage of a complementary mRNA [309]. As dsRNAs can induce 
apoptosis in mammalian cells, through stimulation of interferon expression, direct 
introduction of siRNAs enabled the use of this tool in research cell biology. Molecular 
interaction between siRNA and mRNA depends on the accessibility of the target as it 
was demonstrated in breast cancer cell [205]. In vivo use of siRNA is limited by poor 
cellular uptake and susceptibility to degradation which could be reduced by 
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incorporation within nanoparticles or conjugation with cholesterol. siRNA against IGF-
1R showed down-regulation of the target and decrease of tumor cell growth in 
pancreatic cancer [310], and colon cancer cells [311].  
 
 
 
4.6 IGF system in Ewing sarcoma  
 
The importance of IGF system in ES was first described by Scotlandi et al. in 1996. The 
authors demonstrated the presence of a unique, autocrine loop mediated by IGF-1R in 
ES and PNET cell lines due to an autocrine production of IGF-1. Moreover, blockage of 
the IGF-1R-mediated circuit by anti-IGF-1R αIR3 monoclonal antibody inhibits 
ES/PNET cells growth via increased apoptosis, decrease of proliferation rate as well as 
soft-agar growth and migration upon chemotactic stimulus [312]. Relevance of IGF-1R 
in ES transformation was than demonstrated by Toretsky et al. with an in vitro study 
performed on fibroblasts derived from IGF-1R knockdown or wild type mice. Co-
presence of both EWS-FLI1 and IGF-1R is required for cell transformation as lack of 
one of the two factors prevents soft-agar growth. In addition, EWS-FLI1 alters IGF-1R 
signaling as demonstrated by higher levels of phosphorilated IRS-1, one of the main 
mediators of IGF-1R pathway, compared to cells non expressing the fusion gene [313]. 
Subsequently, a study focused on the identification of EWS-FLI1 target genes 
demonstrated that EWS-FLI1 silencing induces expression of IGFBP-3, a key regulator 
of proliferation signal mediated by IGF-1. ChIP analysis showed that EWS-FLI1 binds 
IGFBP-3 promoter and represses its transcription. In this landscape, inhibition of this 
protein represents a crucial event in ES tumorigenesis [78]. Confirmation of perturbing 
effects of EWS-FLI1 on IGF system were given by other studies performed on 
mesenchymal progenitors: EWS-FLI1 induces expression of IGF-1 and inhibits IGFBP-
3 , IGFBP-5 and IGFBP-7 [66, 78, 314]. Considering the importance of the IGF-
1R/IGF-1 loop in ES pathogenesis, down-stream mediators status was investigated in 
ES cells demonstrating that MAPK and PI3-K pathways appeared to be constitutively 
activated. Utilization of specific inhibitors of MAPK and PI3-K, PD98059 or U0126 
and LY294002, respectively, impaired ES cell growth in monolayer and soft-agar basal 
conditions inducing G1 blockage or affecting cell survival. In addition, MAPK 
inhibition reduced migratory ability of ES cells and increased chemosensitivity to 
doxorubicin, a leader drug in ES treatment [315].  
Considering the relevance of IGF-1R in ES cell growth, efficacy of its inhibition was 
tested in vitro and in vivo. IGF-1R blockage in ES causes inhibition of cancer cell 
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proliferation, survival, and anchorage-independent growth, inhibits tumorigenesis, 
tumor invasion and metastasis, and sensitizes cancer cells to chemotherapy and 
radiotherapy [206]. In vivo, αIR3 monoclonal antibody treatment was shown to induce 
complete tumor regression in 50% of athymic mice [316]. 
 
 
4.7 IGF system in prostate cancer 
 
In the prostate, IGF-1R plays a critical role in normal gland growth and development, as 
well as in cancer initiation and progression [317]. First evidences regarding a putative 
role of IGF system in this tumor type came from epidemiological studies showing that 
higher IGF-1 serum concentration as well as decreased circulating IGFBP-3 correlated 
with increased risk of PCa [318]. Subsequently, several in vitro and in vivo studies were 
performed to assess IGF system role in PCa. Particularly, significance of prostate 
stromal IGF-1 in PCa development was confirmed by Kawada et al.: conditioned 
medium of prostate stromal cells, being rich in IGF-1, induced phosphorilation of IGF-
1R and increased growth of PCa cell lines. Furthermore, only chemical IGF-1R 
inhibitors suppressed the prostate stromal cells-induced growth in PCa cells [319]. It 
was concluded that stromal IGF-1 accelerates tumor growth in prostate. IGF-1R and 
IGFBPs were found expressed in cell lines encouraging researchers to study the putative 
role of IGF-1R in regulating growth, survival and metastases. A study conducted on 54 
samples of primary PCa showed that IGF-1R was significantly up-regulated at protein 
and mRNA levels compared to benign prostatic epithelium. In addition, IGF-1R 
expression was maintained in metastasis samples [320]. This result is in accordance 
with another study showing that intensity of IGF-1R immunostaining increased from 
benign prostatic tumor over PIN to carcinoma [321]. The interaction between androgens 
and IGF system has been considered too and some studies demonstrated that androgens 
induce a selective up-regulation of IGF-1R in PCa cell lines via c-Src/ERK/cAMP–
response element-binding protein (CREB) activation that stimulates IGF-1R promoter. 
Through this mechanism, androgens increase cell proliferation and invasiveness in 
response to IGF-1 thus contributing to the progression to castration-resistant PCa [322, 
323].  
However results in the field of IGF system role in PCa are still controversial. Indeed,  
some studies did not find any significant differences between IGF-1R expression levels 
between normal and tumor tissues [324, 325] while others evidenced a correlation 
between IGF-1R loss and malignancy. In particular, data from an in vitro study reported 
a correlation between progression toward a metastatic stage and reduction of IGF-1R 
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expression [326]. An in vivo study performed by Sutherland et al. showed that in 
conditional (Cre-loxP) prostate-specific IGF-1R knockout mouse model, IGF-1R 
abrogation caused cell proliferation, hyperplasia and emergence of aggressive PCa 
when p53 activity was compromised [327].     
 
 
 
 
 
5. CD99 molecule 
 
 
5.1 MIC2 gene and CD99 protein 
 
CD99 antigen was identified in 1979 thorough 12E7 monoclonal antibody as highly 
expressed in human lymphocytic leukemia cells [328]. CD99, also known as E2, is a 32 
kDa glycoprotein codified by MIC2 gene which is located on pseudo-autosomal region 
of sex chromosomes: X (Xp22.33-Xpter) and Y (Yp11-Ypter). The gene is 50kb and it 
is orientated towards the centromere. MIC2 contains 10 exons that are smaller than the 
average of mammalian genes. In addition, evolutionary studies indicate that the gene 
can be detected by DNA hybridization only in primates [329]. MIC2 does not belong to 
any known gene family but correlates with two genes located in the same pseudo-
autosomal region: PDBX and MIC2R. PBDX codifies for the Xg
a
 blood group antigen 
sharing a 48% homology with CD99 [330] while MIC2R (MIC2-related) is related to 
exons 1, 4 and 5 of MIC2. Transcripts from the MIC2R locus have been detected in all 
human tissues but none of them contains a significant open reading frame making the 
functional role of MIC2R still unknown [331].  
CD99 gene encodes two distinct proteins as a results of alternative splicing process: a 
wild-type full length CD99 or type 1 (CD99wt) and a truncated form or  type II CD99 
(CD99sh). Particularly, the CD99sh was identified in the process of screening a human 
thymus λgt11 cDNA library by Hahn JH et al. in 1997. The CD99sh transcript contains 
a 18-bp insertion at the boundary of exons 8 and 9 of MIC2 gene introducing an in-
frame stop codon that generates truncated polypeptide [332]. The resulting protein 
contains 160 amino acids compared to the 185 amino acids of CD99wt. Conservation of 
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the two isoforms in primates suggests that both of them hold an important role but 
regulatory mechanisms underlying splicing mechanisms are still unknown.  
Sequence analysis of CD99wt cDNA suggests that CD99 contains a 100 amino acids 
extracellular domain glycosilated with O-linked sugars, a putative transmembrane 
domain of 25 amino acids and a 38 amino acids cytoplasmic domain. Biochemical 
studies showed that CD99wt is highly sialylated and glycosylated, it carries no N-linked 
sugar residues while carries O-linked oligosaccharides. Post-translational modifications 
induce a molecular mass reduction going from 32 kDa to 28 kDa and 18 kDa after 
neuraminidase and O-glycanase treatment, respectively [333]. The 32 kDa molecule 
displays a certain similarity with collagen and other glycoproteins including CD43 and 
CD34 involved in cell adhesion processes [334]. More recently, multidimensional 
heteronuclear NMR and CD spectroscopy approaches have pointed out that CD99 
cytoplasmic domain is composed of an α-helical conformation forming a symmetric 
dimmer in the presence of the transmembrane domain. Consequently, no secondary 
structure element seems to be present [335].  
 
 
5.2 CD99 expression in normal and tumor tissues 
 
Immunohistochemical analysis evidenced that CD99 is ubiquitously expressed in 
normal cells and, particularly, an elevated CD99 expression has been found in 
ependymal cells of brain and spinal cord, pancreatic islets, Leydig and Sertoli cells, 
ovarian granulose cells and endothelial cells. Functional role of CD99 in these cells is 
unknown while more information are available regarding its role in hematopoietic 
system. In 1994, Dworzak et al. reported that CD99 is expressed in cells of all leukocyte 
lineages and that its expression is correlated with maturational stages. Particularly, the 
authors evidenced a general highest density of CD99 in the most immature stages of the 
lymphocytic and granulocytic lineages. In the B-lineage cells, CD99 expression is 
observed in the earliest maturational stages characterized by co-expression of CD34 and 
CD10 antigens but is lost during maturation. Similarly, a remarkable CD99 expression 
was observed in immature T-cells while low expression was detected upon 
differentiation [336]. In the erythrocytes, MIC2 product displays a quantitative 
polymorphism co-regulated with Xg
a
 blood group antigen. This co-expression is 
supposed to be regulated at transcriptional level [337].  
In addition to its physiological function, CD99 has a role in pathology and, particularly, 
in cancer. Several evidenced demonstrate its role in acute lymphoblastic leukemia, 
embryonal rabdomiosarcoma, synovial sarcoma, mesenchymal condrosarcoma, gastric 
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and ependimal tumors, in Ewing sarcoma and PNET. Particularly, in Ewing sarcoma 
and PNET,  CD99 represents a diagnostic biomarker together with specific 
chromosomal aberrations [338]. 
Considering that no antibody is able to specifically target CD99sh, RT-PCR represents 
the best technique for CD99 isoforms discrimination. Overall, studies conducted in 
normal and pathological tissues evidenced that CD99sh is expressed at lower levels 
compared to CD99wt but its production may be up-regulated during specific stages of 
cell differentiation, physiologic conditions or locations in the cells [332]. Accordingly, 
it has been described that in immature T-cell lines CD99 is expressed as heterodimers 
composed of a long chain associated with a short variant. During cell differentiation, 
CD99 expression levels decrease putatively because a reduced expression of CD99sh 
[339]. In addition, Lee et al. pointed out an association between CD99 subtypes 
expression and neural differentiation in Ewing sarcoma cells. The authors found that 
CD99sh was reduced upon differentiation while no difference was found in CD99wt 
expression levels. These data suggest that in this tumor type CD99sh acts as a negative 
regulator of neural differentiation [340].   
 
 
5.3 CD99 function in normal and tumor tissues 
 
Physiological functions of CD99 (wild type form) are not completely clear especially 
because its ligand is still unknown and the protein structure still remains not completely 
defined. Use of monoclonal antibodies directed against CD99 allowed identification of 
some functions carried out by CD99. The first studies were performed in hematopoietic 
tissues where CD99 function appears particularly correlated with cellular differentiation 
degree. First evidences in T-lymphocytes pointed out that CD99 presence on the surface 
was involved in spontaneous rosette formation with erythrocytes. As monoclonal 
antibodies directed against CD99 blocked rosette formation [341], the authors 
demonstrated that CD99 mediates T-cell adhesion events. In addition, CD99 activity 
and density was found  related with differentiation stage. Particularly, stimulation with 
MAbs induced homotypic cell aggregation and apoptosis in CD4
+
 and CD8
+
 
corticothymocytes but not in other T cells [342] suggesting a role in cellular 
differentiation. A role of CD99 was also described in peripheral blood lymphocytes as 
anti-CD99 antibodies treatment enhanced T cell proliferation in the presence of anti-
CD3 stimulation and resulted in a marked expression of T-cells activation markers like 
CD69, CD40L [343]. Some studies pointed out that CD99 modulates adhesion of T 
cells to the vascular endothelial cell wall during leukocyte extravasation events. 
50 
 
Particularly, E2 MAbs stimulation was shown to increase affinity/avidity for α4β1 
integrins of peripheral T cells with CD4
+
 memory, but not CD4
+
 virgin T cells, on 
endothelial vascular cell-adhesion molecule 1 (VCAM-1) [344]. In addition, some 
studies evidenced the importance of CD99 expression on endothelial cells for 
monocytes transendothelial migration [345].  
In order to investigate physiologic relevance of CD99 in vivo, Bixel et al. cloned a 
mouse cDNA coding for a protein 45% identical in its sequence with human CD99. 
Antibodies against this mouse homolog were used in leukocites and the results showed 
that the treatment induced blockade of cell aggregation, inhibition of transendothelial 
migration and inhibition of recruitment on in vivo-activated T cells into inflamed skin 
and edema formation [346].  
Some studies evidenced a link between CD99 and osteoblast lineage. In particular, in a 
study performed on osteosarcoma cells, MIC2 gene was demonstrated to be a target of 
Cbfa1, a key transcription factor of osteoblast differentiation. Overexpression of Cbfa1 
was induced in SaOs-2 through transfection of a dominant negative mutant of 
Cbfa1(ΔCbfa1) and this procedure allowed the identification of 4 genes putatively under  
the control of Cbfa1. Between them MIC2 was found as strongly overexpressed in 
mutant cells compared to wild type cells. It is still unclear whether Cbfa1 directly 
regulates transcription of MIC2 or through a signaling pathway.  
Several studies have been carried out to elucidate the role of CD99 in pathology and, 
particularly, in cancer. Overall, data regarding CD99 in tumor point out a dual role of 
this molecule, acting as an oncogene or an oncosuppressor depending on the cellular 
context [347].  
High levels of CD99 were found particularly in ES, where it is also used as a relevant 
diagnostic tool [338]. CD99 stimulation with monoclonal antibodies is reported to 
induce cell death and homotypic adhesion in vitro as well as to reduce cell growth and 
metastasis in vivo [348]. More recently, Rocchi et al. demonstrated, both in vitro and in 
vivo, that silencing of CD99 correlates with an increased neural differentiation as 
demonstrated by neurite-like outgrowth and higher expression of neural differentiation 
markers such as beta-III tubulin and H-neurofilament [94]. In addition, CD99 was found 
as a putative target gene of EWS-FLI1 as demonstrated by ChIP assay results showing 
the recruitment of FLI1 on CD99 promoter in ES cells [94]. Considering CD99 is easily 
accessible, it is expressed in all cases and mediates malignancy in ES, it represents a 
suitable target for specific antibodies with putatively clinical application. With this 
purpose, a nonimmunogenic human recombinant monospecific antibody against CD99 
(dAbd C7) has been recently developed and its efficacy has been tested both in vitro and 
in vivo. dAbd C7 gave satisfactory results in cell lines and in mice when combined with 
51 
 
doxorubicin without affecting viability or differentiation of normal human 
mesenchymal stem cells [349].     
Noteworthy is CD99 role in acute lymphoblastic leukemia as CD99 is found strongly 
expressed in tumor cells compared to normal counterpart [350]. In addition, in this 
tumor type CD99 evaluation represents a putative marker of minimal residual disease 
[351].  
On the opposite side, an oncosuppresive role for CD99 has been postulated in other 
tumors. In lymphomas, in vitro down-regulation of CD99 generates B lymphocytes with 
Hodgkin and Reed-Sternberg phenotype [352]. In pancreatic endocrine carcinomas, 
CD99 is lost in malignant lesions compared to the benign and CD99 loss correlates with 
a worse prognosis [353, 354]. In gastric adenocarcinoma, down-regulation of CD99 was 
found associated with dedifferentiation of tumor cells suggesting a role for this protein 
in tumorigenesis or tumor progression [355]. Studies conducted by Pelosi et al. 
demonstrated the relevance of CD99 in gastrointestinal and pulmonary neuroendocrine 
tumors evidencing a correlation between loss of CD99 positive cells and local invasion 
or distant metastases [356] as well as an association between loss of CD99 and 
occurrence of nodal metastases in patients [357].  
CD99 is reported to act as an oncosuppressor in osteosarcoma as demonstrated by 
Manara et al. In this study, the authors demonstrated that CD99 expression is low or 
absent in osteosarcoma cells and patient specimens compared to normal counterparts. 
As a confirmation, CD99 forced over-expression significantly reduced resistance to 
anoikis, inhibited growth in anchorage-independent conditions and migration as well as 
abrogated tumorigenic and metastatic ability [358]. In addition, a recent study 
evidenced that forced CD99 expression suppresses osteosarcoma cell migration through 
a marked inhibition of ROCK2/ezrin axis [359].  
Sporadic data pointed also out a putative oncosuppressive role of CD99 in prostate 
cancer. Forced over-expression of CD99 in prostate cancer cells causes an inhibition of 
soft-agar growth as well as migration capability. Studies in mice confirmed that cells 
over-expressing CD99 display a decreased tumor incidence and a reduced formation of 
lung or bone metastases [347]. 
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Aim of the study 
 
Aberrant expression of ETS genes due to chromosomal translocations has been 
described as a common feature of different tumor types including Ewing sarcoma and 
prostate cancer. The ETS family includes several transcription factors sharing high 
sequence homology in the DNA binding domain and regulating genes involved in 
cancer initiation and progression. In Ewing sarcoma, EWS-ETS fusion proteins act as 
aberrant transcription factors modulating the expression of a variety of known target 
genes and driving pathogenesis of this tumor. In prostate cancer, the TMPRSS2-ETS 
fusion gene, resulting in over-expression of an ETS member, represents an early event 
in cancer progression but less information are available regarding the target genes 
network dysregulated by this rearrangement. In this study, the impact of TMPRSS2-
ERG on two well documented targets of EWS-FLI1, including components of the 
insulin-like growth factor system and the CD99 molecule, was evaluated. The aim of 
this study was to identify common or distinctive ETS-related mechanisms which could 
be exploited both at biological and clinical level. From the biological point of view, 
identification of target genes for oncogenic ETS transcription factors between different 
tumors may lead to a broader understanding of more general mechanisms underlying 
malignant transformation. From the clinical standpoint, fusion genes and definition of 
their cross-talk may allow identification of molecules with a putative relevance at 
prognostic or therapeutic level. 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
Materials and Methods 
 
CELL LINES 
 
Prostate cancer cell lines PC-3, LNCaP, DU-145, VCaP were obtained from the 
American Type Culture Collection (ATCC). 22RV1 prostate cancer cell line was 
purchased from Sigma Aldrich. Immortalized non-malignant prostate cell line RWPE-1 
and stable trasfectants RWPE-1_tERG or RWPE-1_empty vector were kindly provided 
by Dr. Gambacorti-Passerini, University of Milano-Bicocca. ES cell lines TC-71 and 
6647 were kindly provided by T.J. Triche (Children's Hospital, Los Angeles, CA). LAP-
35 EWS cell line was obtained in the Experimental Oncology Lab, Rizzoli Institute 
(Bologna). PC-3, LNCaP, DU-145, TC-71, 6647 and LAP-35 cells were cultured in 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Lonza). 22RV1 cells were maintained 
in RPMI 1640 (Gibco) while VCaP cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) (Sigma) implemented with L-glucose and bicarbonate. 
RWPE-1 and transfectant cells were maintained in keratinocyte-serum free medium 
supplemented with epidermal growth factor and bovine pituitary extract (Life 
Technologies Inc.). Culture medium of stable trasfectants RWPE-1_tERG or RWPE-
1_empty vector cells was implemented with G418 250μg/ml for selection maintenance. 
IMDM, RPMI and DMEM media were supplemented with 10% inactivated Fetal 
Bovine Serum (FBS) (Lonza) and 100 units/ml penicillin and 100 μg/ml streptomycin.  
Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. All cell lines were 
tested for mycoplasma contamination every 3 months by MycoAlert mycoplasma 
detection kit (Lonza) and were recently authenticated by STR PCR analysis using 
genRESVR MPX-2 and genRESVR MPX-3 kits (Serac). The following loci were 
verified for PCa cells: D3S1358, D19S433, D2S1338, D22S1045, D16S539, D18S51, 
D1S1656, D10S1248, D2S441, TH01, VWA, D21S11, D8S1179, FGA, SE33. For ES 
cells the following loci were verified: D16S539, D18S51, D19S433, D21S11, D2S1338, 
D3S1358, D5S818, D8S1179, FGA, SE33, TH01, TPOX VWA.  
 
 
CLINICAL PROSTATE SPECIMENS 
 
Formalin fixed and paraffin-embedded (FFPE) blocks corresponding to PCa patients 
were retrieved from the archives of the Biobank of the Fundación Instituto Valenciano 
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de Oncología according to the following criteria: specimens obtained from radical 
retropubic prostatectomies from 1996 to 2002 and no history of previous treatment for 
PCa (including androgen deprivation therapy or chemotherapy prior to surgery). 270 
cases were identified to meet these criteria. All patients gave written informed consent 
for tissue donation for research purposes before tissue collection, and the study was 
approved by FIVO’s  Institutional Ethical Committee (ref. number. 2010-19). Clinical 
data were reviewed from clinical records and stored in a PCa-specific database. Patient 
characteristics, including the T2E fusion gene status, and demographics are shown in 
Table 1. Combined Gleason score was uniformly regarded by the same uro-pathologist 
(Ana Calatrava from Fundación Instituto Valenciano de Oncología, Valencia, SPAIN ), 
who also certified high-density cancer areas in haematoxylin and eosin stained slides to 
ensure a purity of at least 75% of cancer cells. For comparative and calibration 
purposes, we also analyzed 10 samples of normal prostate tissue obtained from patients 
operated of radical cystectomies without pathological evidence of prostatic disease. T2E 
gene fusion status was determined by RT-PCR and fluorescent in situ hybridization 
(FISH) as described by and quantitative RT-PCR. Follow-up of the retrospective series 
ranged from 2 to 189 months (median 96 months). Biochemical progression was 
defined as serum PSA greater than 0,4ng/ml during follow-up and clinical progression 
was defined as local (prostatic fossa), regional (lymph nodes) or distant (metastasis) 
progression.  
 
 
DRUGS 
 
Anti-IGF-1R drugs were kindly provided by: ImmunoGen Inc. (AVE1642, a humanized 
version of anti-IGF-1R EM164 antibody), Pfizer (CP-751,871/Figitumumab), and 
Novartis (NVP-AEW541). Abiraterone acetate (S1123) and Cabazitaxel (S3022) were 
purchased by Selleckchem. Trabectedin was provided as lyophilized formulations and 
as clinical preparation by PharmaMar S.A., Colmenar Viejo, Madrid, Spain. OSI-906 
(Linsitinib)  was purchased by Selleck Chemicals. Doxorubicin (DXR) was purchased 
from Sigma-Aldrich (St. Louis, MO, USA). Working dilutions of all drugs were 
prepared immediately before use.  
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GENE EXPRESSION ANALYSIS 
 
Cell line analysis 
 
Cell lines total RNA (2 mg) was extracted with TRIzol (Invitrogen), a monophasic 
solution of phenol and guanidine isothiocynate, and purified by precipitation with 
isopropanol.  Oligo dT primers (Applied Biosystems) were used to reverse transcribe 
RNA with a 260/280 nm absorbance ratio of 1.5-2. Quantitative Real-Time PCR was 
performed on ABI Prism 7900 (Applied Biosystems) using TaqMan or SYBR Green 
assays (Applied Biosystems). Following predesigned TaqMan assay for target gene was 
used: IGF-1R (Hs00181385_m1), CD99 (Hs00365982_m1). Following SYBR Green 
assays for target genes were used: IR (forward 5’-
CGTGGAGGATAATTACATCGTGTT-3’ and reverse 5’- 
TGGTCGGGCAAACTTTCT -3’, 167bp), IGF-1 (forward 5’- 
TCGCATCTCTTCTACCTGGCGCTGT-3’ and reverse 5’- 
GCAATACATCTCCAGCCTCCTAGA-3’, 240bp), IGF-2 (forward 5’- 
GACCGCGGCTTCTACTTCAG -3’ and reverse 5’- 
AAGAACTTGCCCACGGGGTAT -3’, 203bp).     Primer Express software (Applied 
Biosystems) was used to design appropriate primer pairs and probe for reference gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH): forward 5’- 
GAAGGTGAAGGTCGGAGTC-3’, reverse 5’- GAAGATGGTGATGGGATTTC -3’ 
and probe 5’- CAAGCTTCCCGTTCTCAGCC -3’. Two replicates per gene were 
considered. Relative quantification analysis was performed on 2
-ΔΔCt
 method. Absolute 
quantification assay for the measurement of total IGF-1R was performed by Dr. Roberta 
Malaguarnera accordingly to the procedure published in 2011 [360]. 
 
Clinical specimens analysis 
 
Isolation of RNA from three sections of 10μm paraffin-embedded tissue was performed 
using RecoverAll™ Total Nucleic Acid Isolation Kit (Ambion) following providers’ 
specifications. RNA with a 260/280 nm absorbance ratio of 1.5-2 was reverse 
transcribed with High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
according to manufacturer’s indications. Clinical samples were analyzed using ABI 
7500-Fast Thermocycler Sequence Detection System (Applied Biosystems), according 
to manufacturer’s instructions. Predesigned TaqMan probes for target genes were used: 
IGF-1R (Hs00181385_m1), IR (Hs00961560_m1), IGFBP-3 (Hs00426287_m1), IGF-1 
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(Hs 00153126_m1), IGF-2 (Hs04188276_m1), CD99 (Hs00365982_m1), T2E 
(Hs03063375_ft). For endogenous control β-2-microglobulin: (Hs99999907_m1) was 
used (Applied Biosystem). 
cDNA from normal human prostate samples was used as calibrator for comparative 
analysis of PCa cases. Two replicates per gene were considered. Relative quantification 
analysis was determined using the mean value of the control samples and following the 
2
-ΔΔCt
 method.  
 
 
CHROMATIN IMMUNOPRECIPITATION (ChIP) 
 
For ChIP assay cells plated in 60 or 100 mm Ø dishes were washed twice with PBS and 
crosslinked with 1% formaldehyde at 37°C for 10 minutes. Cells were than washed with 
fresh PBS, collected, resuspended in lysis buffer (1% SDS, 10mM EDTA, 50mM Tris-
HCl pH 8.1) and kept in ice for 10 minutes. Cells were then sonicated four times for 10 
seconds at 30% of maximal power and collected by centrifugation at 4°C for 10 minutes 
at 14000 rpm. Supernatants were collected and diluted in IP buffer (0.01% SDS, 1.1% 
Triton X-100, 1.2mM EDTA, 16.7mM NaCl) and precleared with sonicated salmon 
sperm DNA/ protein A agarose (UBI) for 1 hour at 4°C. Precleared chromatin was 
immunoprecipitated for 12 hours with anti-ERG-1/2/3 (C-17, Santa Cruz 
Biotechnology) or anti-FLI1 antibodies (C-19, Santa Cruz Biotechnology). Salmon 
sperm DNA/ protein A agarose was added and precipitation was continued for 4 hours 
at 4°C. Pellet was collected and the precipitates were washed sequentially for 5 minutes 
with the following buffers: Wash A (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl pH 8.1, 150mM NaCl), Wash B (0.1% SDS, 1% Triton X-100, 2mM EDTA, 
20mM Tris-HCl pH 8.1, 500mM NaCl), Wash C (0.25M LiCl, 1% NP-40, 1% sodium 
deoxycholate, 1mM EDTA, 10mM Tris-HCl pH 8.1), and twice with TE buffer (10mM 
Tris, 1mM EDTA). The immune complexes were eluted with elution buffer (1% SDS, 
0.1M NaHCO3). The eluates were reverse crosslinked by heating at 65°C for 12 hours 
and digested with proteinase K (0.5mg/ml) at 45°C for 1 hour. DNA was obtained by 
phenol/chloroform/isoamylalcohol (25:24:1) extractions. Yeast tRNA was added to 
each sample and DNA was precipitated with EtOH for 12 hours at 4°C and resuspended 
in TE buffer. Samples were quantified with Nanodrop. Quantitative RT-PCR was 
performed with custom primers flanking Ets-containing target promoters fragment. 
IGF-1R promoter was evaluated by Real-Time PCR using the following custom 
TaqMan assay: forward 5’-AGGAGGAGGAGGAGGAGGAG-3’, reverse 5’-
GCAGTTCGCAAGATCGCC-3’ and probe 5’-TTGACTCCGCGTTTCTGCCCCTCG-
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3’. For the TaqMan assay design TFSEARCH - Searching Transcription Factor Binding 
Sites, version 1.3 free website was used for the prediction of ETS binding sites in the 
promoter of IGF-1R gene and the sequence spanning from 1041bp to 1051bp was 
identified as the best. Beacon Designer 4 software was used for the design of the assay 
spanning from 1005bp to 1114bp. PIM-1 promoter fragment containing ETS consensus 
sequence was used as ERG immunoprecipitation positive control [174] by Real-Time 
PCR using the following SYBR Green assay: forward 5'-
GTGCTAGGCGAGTGGGAACAACTG-3' and reverse 5'-
AATGACCCAAATTCACCTCCTGAG-3'. CD99 and TGFβR2 promoter fragments 
containing ETS consensus sequence were evaluated with the following SYBR Green 
assays: CD99 promoter forward 5’- TTGTTAAGTGTGGGAAGGGC-3’ and reverse 
5’- CTGCTCACCTCAGGGAGTTC-3’ (417bp), TGFβR2 promoter 5’- 
GTGTGGGAGGGCGGTGAGGGGC-3’ and reverse 5’- 
GAGGGAAGCTGCACAGGAGTCCGGC-3’(285bp). For quantitative PCR (qPCR) 
data are calculated with the following formula: % of recruitment = 2
ΔCt 
x input 
chromatin percentage, where ΔCt = Ct (input) - Ct (ETS IP) in accordance to Frank SR 
et al [361].   
 
 
IMMUNOHISTOCHEMISTRY 
 
PCa specimens were incorporated in 11 tissue microarrays (TMA). Two or three 
representative areas (1 mm in diameter) of each tumor were selected for TMA 
production by first examining hematoxylin and eosin-stained prostatectomy tumor 
slides and then sampling tissue from the corresponding paraffin blocks. A tissue 
microarray instrument (Beecher Instruments) was used for TMA assembly. From TMA 
blocks, 3-μm-thick sections were immunostained using rabbit anti-human IGF-1Rβ C-
20 sc-713 (Santa Cruz Biotechnology), anti-human IRβ C-19 sc-711 (Santa Cruz 
Biotechnology), mouse anti-CD99 or anti-human ERG clone EP111 polyclonal-Ab 
(Dako). Percentage of positive cells and cytoplasmic staining intensity were scored 
semiquantitatively, forming four groups (from 0 to 3). Cases were scored as low 
expression when staining intensity was between 0 and 1, and high expression when 
intensity was 2 and 3. 
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IN VITRO ASSAYS   
 
To assess drug sensitivity, MTT assay (Roche) was used according to manufacturer’s 
instructions. Cells were plated into 96 well-plates (range 2,500-10,000 cells/well). After 
24 hours, various concentrations of AVE1642 (0.01-50 µg/ml), NVP-AEW541 (0.03-5 
µM), CP-751,871 (0.5-500 µg/ml), trabectedin (0.3-3 nM), OSI-906 (0.3-3 µM) or 
Abiraterone acetate (1-100μM) were added and cells exposed to these drugs for up to 72 
hours. Short interfering RNA knockdown of ERG was performed with siRNA from 
Thermo Scientific Dharmacon: siGENOME_siRNA (D-003886-01). siGENOME_non 
targeting_siRNA was used as control (D-001210-01-05). siRNA was transfected in 
VCaP cells using siport NeoFX transfection agent (Life Technologies Inc.) according to 
manufacturer’s instructions. Silencing was assessed after 48, 72, 96 and 120 hours from 
transfection. VCaP cells were pre-treated with ERG siRNA (100nM) for 48 hours and 
then exposed to CP-751,871 (0,01-1 µg/ml), NVP-AEW541 (0.2-2 µM) or Abiraterone 
(3-30 µM) for 72 hours. Cell growth was assessed with Trypan Blue. ERG and IGF-1R 
protein expression was investigated upon 72, 96 and 120 hours of Abiraterone treatment 
(3-10 µM). Short interfering RNA knockdown of EWS-FLI1 was performed with 
Lipofectamine (Invitrogen) following the manufacturer’s protocols. siRNA was used at 
concentrations of 75 or 100 nM for 24 hours and siRNA sequences are the following: 
CACCCACGTGCCTTCACAC targeting the 3’ portion of FLI1 (IDT). On-TargetPlus 
NonTargeting Pool (Thermo Scientific Dharmacon) was used as scrambled control. For 
combined treatments, cells were treated for 72h with drugs alone or combined in fixed 
ratios. VCaP cells were treated for 72 hours with varying concentrations of CP-751,871 
(1-100 µM) and Abiraterone (1-100 µM) or Cabazitaxel (0.003-0.3 µM). In Trabectedin 
and OSI-906 combination experiments, ES cells were treated in fixed ratio 1:1000 while 
PCa cells were treated in fixed ratio 1:100.   
 
 
WESTERN BLOTTING 
 
Proteins were collected from cells plated in 60 or 100 mm Ø dishes with a sub-
confluence status. Cell lysis was performed on ice with UPSTATE buffer for 
phophorilated proteins (50mM Tris-HCl pH 7.4, 150mM NaCl, 1% NP-40, 1mM 
EDTA, 0.25% sodio deossicolato, 1mM NaF) upon addition of proteases inhibitors 
(1:100): aprotinin (10µg/ml), leupeptin (0.1mM), PMSF (1mM), sodium orhtovanadate 
(0.2mM). After 30 minutes incubation, lysates were centrifuged and proteins from 
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solution fraction were collected. Protein concentration was obtained upon dilution in 
Protein Assay (Bio-Rad) (1μl in 999μl) and spectrophotometer reading compared to a 
standard curve. Equivalent amounts of total cell lysates were separated by 10% SDS-
PAGE under denaturating conditions and transferred onto nitrocellulose membrane 
(Bio-Rad). Ponceau (Sigma-Aldrich) staining was used to evaluate transfer quality. 
Membranes were blocked for 1 hour at room temperature with milk diluted in TBST (10 
mM Tris-HCl ph 7.4, 150 mM NaCl e 0.1% Tween20) and than incubated overnight 
with the following primary antibodies: anti-IGF1-Rβ, anti-IRβ, anti-GAPDH, anti-
LAMIN B, anti-ERG-1/2/3, anti-FLI1 (Santa Cruz Biotechnology), anti-AR (Cell 
Signaling Technology), anti-actin, anti-CD99. Membranes were then incubated with 
secondary anti-rabbit or anti-mouse antibodies conjugated to horseradish peroxidase 
(Amersham) and revealed by ECL Western blotting detection reagents (GE Healthcare).   
 
 
STATISTICAL ANALYSIS 
 
Differences among means where analyzed using two-sided Student’s t test. Drug-drug 
interactions combination index (CI) was calculated with the isobologram equation of 
Chou-Talalay [362] by using CalcuSyn software (Biosoft). IC50 values were determined 
using CalcuSyn software (Biosoft).Correlations analysis were performed using Fisher’s 
exact test. Kaplan-Meier proportional risk log rank test was applied for survival curves. 
BPFS and PFS were considered individually from the date of surgery to the date of 
event. Univariate predictors of outcome were entered into a Cox proportional hazard 
model using stepwise selection to identify independent predictors of prognosis, 
considering the 95% CI.    
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Table 2. Clinicopathologic features of PCa patients evaluated for IGF system components 
and CD99 expression by qRT-PCR or by IHC. 
  
qRT-PCR (n = 270) 
 
IHC (n =  243) 
Parameter  No. Pts  %  
 
No. Pts  %  
Age 
 
  
      ≤ 55 15 5,6  
 
12 5 
  56-65 81 30  
 
74 31 
  66-75 138 51,1  
 
124 52,1 
  > 75 36 13,3  
 
28 11,7 
Gleason-sp:  
        2-6  109 40,4  
 
87 36,4 
   7  129 47,8  
 
123 51,4 
   Greater than 7  32 11,9  
 
29 12,1 
PSA (ng/ml):  
        10 or less  154 57 
 
132 55,6 
   10-20  74 27,6  
 
69 29,1 
   Greater than 20  40 14,9  
 
36 15,1 
cT:  
        cT2b or less  248 92,2  
 
219 92 
   cT3a or greater  21 7,8  
 
19 7,9 
pT:  
        pT2 or less  135 50  
 
115 48,1 
   pT3 or greater  135 50  
 
124 51,8 
pN*:  
        pN0  236 95,2  
 
209 95,4 
   pN1 or greater  12 4,8  
 
10 4,5 
Margins:  
        Negative  137 50,7  
 
116 48,5 
   Positive  133 49,3  
 
123 51,4 
TMPRSS2/ERG**  
        Negative  92 34,1  
 
102 46,5 
   Positive  178 65,9  
 
117 53,4 
 
SP, specimen; cT, clinical stage; PSA, prostatic specific antigen; pN, lymphnode pathological stage  
*Lymphadenectomy was limited to the obturator fossa in most of the cases at the inclusion period  
**IHC ERG expression was not detectable in 24/243 and negative in 85/219 cases (39%) 
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Results 
 
1. TMPRSS2-ERG and IGF system 
 
1.1 Analysis of IGF system main components expression in PCa cell lines 
 
A panel of six prostate cell lines, including malignant VCaP, DU-145, PC-3, LNCaP, 
22RV1 and the non-malignant RWPE-1 cells was analyzed for the basal expression of 
different components of the IGF system. The panel of cell lines was characterized by 
different expression levels of androgen receptor (AR) and the TMPRSS2-ERG (T2E) 
gene fusion presence. VCaP cell line was the only one characterized by expression of 
T2E as limited models of PCa cell lines constitutively expressing T2E are available. As 
shown in figure 7, T2E presence corresponds to a high expression of ERG transcription 
factor.  
 
 
Figure 7. Western blotting analysis of 
AR and ERG1/2/3 expression in a 
panel of PCa cells. GAPDH is shown 
as a loading control. 
 
 
No IGF-1 or IGF-2 expression was detected in cell lines confirming a paracrine 
activation of the IGF pathway, putatively exploited by the stroma, in this tumor. As 
shown in figure 8, IR was found generally higher in PCa cells with respect to normal 
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cells. IGF-1R expression was found lower in PCa cells compared to RWPE-1 cell line 
with the only remarkable exception of VCaP cells both at mRNA and protein levels. 
These data suggested a potential correlation between tERG and IGF-1R.  
 
 
 
 
 
 
Figure 8. Evaluation of IGF-1R and IR basal expression in prostate cell lines. Relative 
mRNA expression levels (top) of IGF-1R and IR in prostate cancer cell lines. The 
RWPE-1 cell line was used as a calibrator (2
-ΔΔCt
 = 1). Protein expression levels of 
receptors in prostate cells (bottom). The blots are representative of two independent 
experiments.  
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1.2 Functional evaluation of tERG/IGF-1R correlation in PCa 
 
For a comprehensive evaluation of the putative relationship between T2E and IGF-1R, 
different approaches were followed and are shown in figure 9. First, a transient 
silencing with siRNA directed against ERG was performed in VCaP cells. Interestingly, 
upon 96 and 120 hours of ERG silencing a down-modulation of IGF-1R was evidenced 
at protein levels compared to untreated cells or scrambled (Figure 9A). Second, IGF-1R 
expression was evaluated in RWPE-1 cells stably transfected for tERG overexpression 
(RWPE-1_tERG). The analysis pointed out that over-expression of ERG corresponded 
to a higher expression of IGF-1R both at mRNA and protein levels (Figure 9B). Third, 
as T2E fusion gene is regulated by androgens,  IGF-1R expression was investigated in 
VCaP cells upon abiraterone acetate stimulation. Abiraterone acetate is a second-
generation anti-androgen drug that blocks the synthesis of androgens. VCaP cells were 
treated for 72, 96 and 120h with two concentrations of abiraterone acetate and western 
blotting analysis showed that together with a strong ERG down-regulation, IGF-1R 
levels decreased upon 10 µM treatment in VCaP cells (Figure 9C).  
To better address the role of tERG in IGF-1R modulation, putative transcriptional 
regulation of ERG on IGF-1R promoter was investigated. An anti-ERG chromatin 
immunoprecipitation (ChIP) assay was performed in VCaP and PC-3 cells which 
express ERG at high or low levels, respectively, as well as in RWPE-1_tERG and 
RWPE-1 empty vector transfected cells. As shown in figure 10, ChIP analysis indicated 
that ERG binds the IGF-1R gene promoter, and the amount of binding was higher in 
cells with tERG expression. Considering the  increase at mRNA levels in VCaP and 
RWPE-1_tERG compared to PC-3 or empty vector-transfected cells (Figures 8 and 9), 
the results indicate that ERG directly regulates IGF-1R transcription in PCa and that the 
increased amount of ERG due to fusion gene causes the higher IGF-1R expression in 
T2E-positive cells.   
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Figure 9. tERG-dependent IGF-1R induction in prostate cancer cells. A, siRNA knockdown of 
ERG (siERG) in VCaP induces a decrease in IGF-1R levels compared with non-treated control 
(NT) or non-targeting siRNA (SCR) controls. B, IGF-1R is over-expressed in RWPE-1 cells 
transfected with tERG compared with controls both at mRNA and protein level. Absolute IGF-
1R mRNA quantification was assessed in RWPE-1 cells over-expressing t-ERG or empty 
vector-transfected cells (left). The blots are representative of two independent experiments 
(right). C, Abiraterone acetate treatment induces down-regulation of ERG in VCaP cells and 
IGF-1R. Cells were treated with abiraterone (3 and 10 µM) for the indicated time points. 
Representative blots are shown. GAPDH was used for normalization. 
 
A 
B 
C 
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Figure 10. ERG acts as a stimulatory transcription factor in PCa cells. ChIP assay (top) was 
performed on VCaP and PC-3 prostate cancer cells, as well as on tERG- or empty vector-
transfected RWPE-1 cells. ERG was precipitated with an anti-ERG-1/2/3 antibody. The 
results were obtained by quantitative RT-PCR. The data represent the recovery of each DNA 
fragment relative to the total input DNA. A representative experiment is shown. Cartoon 
(bottom) of the androgen/T2E/IGF-1R axis described in this study.   
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1.3 Efficacy of anti-IGF-1R agents in prostate cancer cells  
 
As described in introduction section, several agents have been developed to specifically 
target IGF-1R on the basis of its importance in sustaining cell growth of different 
tumors. In PCa, several preclinical and clinical studies testing the effects of these agents 
have been performed and evidenced a limited efficacy. In this field, relevance of T2E in 
modulating the response to this type of treatment has been never considered.  
PCa cell lines were exposed for 72 hours to increasing concentrations of CP-751,871 or 
AVE1642, two anti-IGF-1R HAbs, as well as NVP-AEW541, a selective IGF-1R 
tyrosine kinase inhibitor (TKI). As shown in figure 11, an overall resistance to these 
agents was evidenced in the analyzed panel of cells with the exception of VCaP cells 
showing a remarkably high sensitivity to all anti-IGF-1R agents.  
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Figure 11. Sensitivity to IGF-1R inhibition in PCa cells. Cell growth was 
assessed using an MTT assay after a 72-h exposure to CP-751,871 or 
AVE1642, two anti-IGF-1R-HAbs, and NVP-AEW541, an anti-IGF-1R 
tyrosine kinase inhibitor (TKI) in prostate cell lines. The results are 
displayed as the percentage of survival relative to controls. Points, mean 
of two independent experiments; bars, SE.   
 
 
 
 
 
To address the role of T2E/IGF-1R axis in influencing sensitivity to anti-IGF-1R agents, 
VCaP cells were transiently transfected with anti-ERG siRNA for 48 hours and treated 
with two concentrations of CP-751,871 HAb or NVP-AEW541 TKI corresponding to 
the doses conferring 20 and 50% of cell growth inhibition. Cell count showed that ERG 
expression significantly influenced efficacy of anti-IGF-1R agents as its silencing 
reverted cell sensitivity toward CP-751,871 or NVP-AEW541 in VCaP cells (Figure 
12).  
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Figure 12. tERG overexpression increases sensitivity to anti-IGF-1R agents. ERG 
silencing was achieved in VCaP cells after a 48-h transfection of siERG (100 nM) or 
scrambled control siRNA (100 nM); GAPDH was used as a loading control. Cell survival 
is shown as the percentage of growth respect to untreated control. The data represent the 
mean values of two independent experiments, and the bars represent the SE.  
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1.4 Combinatory treatment of anti-IGF-1R therapy and anti-androgens  
 
In PCa, anti-IGF-1R inhibitors effects have been investigated in combination with 
other drugs such as mitoxantrone (NCT00683475) or docetaxel [363]. TMPRSS2-
ERG is driven by androgens and, consequently, all its down-stream effects can be 
putatively affected by androgens deregulation. In this landscape, sensitivity to 
abiraterone acetate was first assessed in a small panel of PCa cells. Accordingly to 
hormone response features, VCaP cells displayed a sensitivity to abiraterone 
acetate, with an calculated IC50 of 20µM (Figure 13), while PC-3 and DU-145 
cells were substantially resistant to the treatment. In VCaP cells, the doses of 3 
and 30µM, conferring 20 and 50% of cell growth inhibition, respectively, were 
chosen for further experiments.   
 
 
 
Figure 13. Sensitivity to Abiraterone acetate in PCa cells. Cell growth was assessed using 
an MTT assay after a 72-h exposure to Abiraterone acetate at the indicated doses. Results 
are displayed as the percentage of survival relative to controls. Points, mean of two 
independent experiments; bars, SE.     
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Response to abiraterone acetate in VCaP cells upon ERG silencing was 
investigated. As already demonstrated in literature, patients harboring T2E better 
respond to hormone treatment. Accordingly, ERG deprivation in VCaP cells 
induced a significant decrease in sensitivity to abiraterone stimulation compared 
to non treated or scrambled controls (Figure 14). 
 
 
 
Figure 14. Reversion of sensitivity to abiraterone acetate by ERG knockdown. ERG 
was silenced in VCaP cells with siERG (100 nM) or scrambled control siRNA (100 
nM); GAPDH was used as a loading control. Cells were treated with abiraterone acetate 
for 72 h at the indicated doses, and the survival percentage with respect to untreated 
control is shown. The data represent the mean values of two independent experiments, 
and the bars represent SE. 
 
 
Interestingly, simultaneous administration of CP-751,871 and Abiraterone acetate 
but not cabazitaxel, a microtubule inhibitor recently introduced in PCa treatment, 
induced synergistic anti-proliferative effects in VCaP cells. In figure 15, 
individual doses of CP-751,871, abiraterone acetate or cabazitaxel to achieve 90% 
growth inhibition (blue line; ED90), 75% growth inhibition (green line; ED75) 
and 50% (red line; ED50) growth inhibition are plotted on the x- and y- axes. 
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Drug-drug interaction was classified as synergistic when CI was lower than 0.90, 
as additive when 0.90≤CI≤1.10, or as subadditive when CI was higher than 1.10.   
 
 
               
 
Figure 15. The combination of an IGF-1R inhibitor with 
Abiraterone acetate (top), but not cabazitaxel (bottom), results 
in synergistic effects in TMPRSS2-ERG-positive cells. The CI 
values representing ED90 are reported.    
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2. ETS rearrangements and IGF-1R expression in Ewing 
sarcoma 
 
Considering the results obtained in PCa regarding ERG capabilities to regulate IGF-1R 
gene expression, activity of EWS-FLI1 on IGF-1R was investigated. EWS-FLI1 is the 
hall mark of ES and several studies have been performed in the past years in order to 
evidence target genes that could be de-regulated by EWS-FLI1. EWS-FLI1 has been 
already demonstrated to influence transcriptional regulation of some IGF system 
components, including IGF-1 and IGFBP-3, but not IGF-1R [92].  
To address the EWS-FLI1 activity on IGF-1R, ES cell line TC-71 was transiently 
transfected with two concentrations of anti-FLI1 siRNA and protein expression of FLI1 
and IGF-1R was evaluated by western blotting. As shown in figure 16, knock-down of 
EWS-FLI1 induced a down-regulation of IGF-1R protein highlighting a new interesting 
mechanism in ES biology. Moreover, an anti-FLI1 chromatin immunoprecipitation 
(ChIP) assay was performed in TC-71, 6647 and LAP-35 ES cell lines. TC-71 
represents a model of EWS-FLI1 type 1 chimera while 6647 and LAP-35 cells display 
EWS-FLI1 type 2 hybrid. ChIP analysis evidenced the recruitment of FLI1 to IGF-1R 
promoter in all of the cellular models (Figure 17).  
 
 
 
 
Figure 16. EWS-FLI1 knockdown in 
TC-71 cells induces a decrease in 
IGF-1R levels compared with non-
treated control or scrambled control.   
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Figure 17. EWS-FLI1 basal recruitment on IGF-1R 
promoter in three ES cell lines. Results were obtained 
by quantitative RT-PCR. The data represent the 
recovery of each DNA fragment relative to the total 
input DNA. The data represent the mean values of two 
independent experiments, and the bars represent the 
SE. 
 
 
 
  
3. Effects of Trabectedin (ET-743, Yondelis
TM
) on ETS 
fusion genes binding to IGF-1R promoter 
 
Recently, capability of DNA binding agents including trabectedin has been 
demonstrated to modulate activity of transcription factors, introducing a certain 
specificity and a new level of complexity in the action of conventional agents. Such 
effects have been already described in myxoid liposarcoma and ES where trabectedin 
interferes with the activity of FUS-CHOP and EWS-FLI1, respectively, justifying the 
elevated sensitivity to trabectedin of tumors harboring fusion genes. Trabectedin is a 
tetrahydroisoquinoline molecule that binds to the N2 of guanine in the minor groove, 
causing DNA damage and affecting transcription regulation in a promoter- and gene-
specific manner. In this study, the effects of trabectedin on IGF-1R were investigated 
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based on the evidence that ES cell variants resistant to trabectedin displayed an up-
regulation of IGF-1R and IRS-1 gene expression compared to parental cells [364].  
 
3.1 Evaluation of EWS-FLI1 binding to IGF-1R promoter upon stimulation 
with trabectedin 
 
Trabectedin is one of the very few novel drugs recently proposed for the treatment of 
sarcoma patients. However, the activity observed in ES was quite modest in the clinical 
setting. Identification of mechanisms that could improve the efficacy of trabectedin in 
ES represents the main goal to optimize the use of this drug.  
The study was performed in TC-71 and 6647 cell lines as representative models of type 
1 and type 2 EWS-FLI1 chimera, respectively. Anti-FLI1 ChIP assay and Real Time-
PCR were performed to monitor the binding of EWS-FLI1 to a conventional target 
gene, TGFβR2, as well as IGF-1R promoter upon trabectedin or doxorubicin (DXR) 
stimulation. Cell lines were treated with different concentrations of trabectedin or DXR 
for 1 hour, IC50 doses were calculated and used for the experiments. Treatment with 
Trabectedin (2.5nM and 10nM, respectively) or DXR (1μM and 2μM, respectively) 
induced a significant reduction of EWS-FLI1 binding to TGFβR2 promoter (Figure 18). 
Conversely, trabectedin but not DXR caused an increased recruitment of EWS-FLI1 on 
IGF-1R promoter. As shown in figure 19, occupancy of EWS-FLI1 to IGF-1R promoter 
was dose- and time-dependent. Interestingly, trabectedin-induced up-regulation of the 
IGF-1R was also confirmed at protein level and the analysis pointed out that IGF-1R 
increase was maintained up to 48 hours (Figure 19).      
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Figure 18.  Trabectedin induces detachment of EWS-FLI1 from specific promoters. ChIP 
assay results were obtained by quantitative RT-PCR and data are reported as fold 
enrichment over the control. * p<0.05; ** p<0.001, Student’s t test.  
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Figure 19. Trabectedin induces recruitment of EWS-FLI1 on IGF-1R promoter in ES cells. A, 
ChIP assay results in TC-71 and 6647 ES cells treated for 1h with trabectedin or DXR. Data 
represent recovery of each DNA fragment relative to total input DNA, respect to control.  
* p<0.05; Student’s t test. B, Time-course of EWS-FLI1 association with IGF-1R promoter 
evaluated by quantitative RT-PCR in TC-71 cells. Bars represent SE. * p<0.05; ** p<0.001, 
Student’s t test. C, Up-regulation of IGF-1R at protein level by western blotting after exposure 
of TC-71 cells to trabectedin (0.5-1 nM) up to 48h. GAPDH was used as loading control. 
A 
B 
C 
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3.2 Evaluation of tERG binding to IGF-1R promoter upon stimulation with 
trabectedin 
 
Evidences regarding efficacy of trabectedin as single agent in PCa are limited to one 
phase II clinical trial carried out in metastatic castration-resistant patients. In this 
population of PCa patients, few therapeutic options are available and the strategies 
currently in use confer transient benefits evidencing that additional agents are needed. 
In the study conducted by Michaelson et al., Trabectedin was administered following 
two schedules but the results evidenced modest activity of this agent with a 13% of 
patients experiencing a PSA decrease ≥50% [365]. Identification of patients with 
specific molecular features who could benefit of trabectedin treatment could improve 
use of this agent in clinic.  
In this study, VCaP cells were treated for 1h with two doses of trabectedin (1 and 3nM) 
and ChIP assay with anti-ERG antibody was performed. Doses were decided based on 
cell count upon 1h treatment with a range of concentrations of trabectedin. ChIP assay 
showed that trabectedin is able to displace ERG binding to PIM-1 promoter, a 
conventional ERG target gene. Conversely to the results obtained in ES, trabectedin also 
induced ERG detachment from IGF-1R promoter, evidencing a cellular-dependent 
activity of trabectedin on IGF-1R promoter. Results of ChIP assay are shown in figure 
20.  
 
 
Figure 20. ChIP assay results displaying that Trabectedin reduces ERG binding to PIM-1 as 
well as IGF-1R promoter in VCaP cell line after 1 hour of treatment. Results were obtained by 
quantitative RT-PCR and data are reported as fold enrichment over the control. ** p<0.001, 
Student’s t test.     
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3.3 Therapeutic implications of trabectedin gene-specific effects 
 
Considering the increased IGF-1R expression in ES cells upon treatment with 
trabectedin and the importance of IGF-1R in sustaining ES cells growth, TC-71, 6647 
and LAP-35 cell lines were treated with a combination of trabectedin and the anti-
IGF1R/IR dual inhibitor OSI-906. OSI-906 was chosen because it has been already 
reported that high levels of IR can overcome IGF-1R blockade in ES cells. Interestingly, 
the combined treatment gave synergistic effects in ES cell lines. On the contrary, 
combination of trabectedin with OSI-906 gave subadditive effects in VCaP PCa cells 
harboring T2E rearrangement, according to inhibitory effects of trabectedin on IGF-1R 
promoter occupancy (Table 3). 
These results suggest that a combination of trabectedin and anti-IGF-1R inhibitor 
represents a new potential therapeutic option for ES but not for PCa patients. 
 
 
 
 
 
Table 3. Efficacy of Trabectedin and OSI-906 as single agents or in combination in ES and 
PCa cell lines. 
Cell line Trabectedin (nM) 
 IC50 ± SE 
OSI-906 (µM)  
IC50 ± SE 
Dose ratio Drug combination 
CI ± SE 
Effect 
TC-71 0.13 ± 0.01  0.4 ±  0.15 1:1000 0.819±0.01 synergistic 
6647 0.22 ± 0.09 1.25 ± 0.45 1:1000 0.687±0.06 synergistic 
LAP-35 0.14 ± 0.03 0.17 ± 0.07 1:1000 0.734±0.08 synergistic 
VCaP 1.96 ± 0.12 0.18 ± 0.5 1:100 1.43 ± 0.05 subadditive 
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4. Prognostic relevance of IGF system and assessment of 
TMPRSS2-ERG/IGF-1R axis in PCa patients 
 
4.1 Gene expression profile of IGF system in primary PCa 
Clinical role of IGF system was previously investigated in ES in order to identify 
patients with distinct outcome and putatively different treatment protocols. Results 
showed that transition to frank malignancy is associated with a reduction of IGF system 
activity [282]. Prognosis value of IGF system and mainly of IGF-1R in PCa still 
remains controversial. Noteworthy, T2E has been already reported to identify patients 
with different clinico-pathological characteristics and different prognosis. Gene 
expression of IGF-1R, IR, IGF-1, IGF-2 and IGF-BP3 was evaluated in a retrospective 
series of 270 primary prostate tumors by Real-Time PCR (Table 2). While no IGF-2 
expression was detected in samples, differential expression of IGF-1R, IGF-1, IGFBP-3 
and IR was compared to normal prostate tissues following the 2
-∆∆Ct
 method. As shown 
in figure 21, no differential expression with respect to normal tissue was noticed for 
IGF-1R (median=1,04; range=0,07-5,12), while a variable expression was evidenced for 
IGF-1 (median=0,61; range=0,01-50,12) and IR (median=0,58; range=0,01-471,75). 
IGFBP-3 was found to be substantially down-regulated (median=0,52; range=0,05-
2,96).  
 
Figure 21. IGF system expression profile in prostate cancer patients.     
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Expression of the genes was classified in “high” and “low” expression depending on if 
obtained RQ values were above or below the first quartile respectively. The association 
of IGF-1R, IR, IGF-1 and IGF-BP3 expression with clinico-pathological characteristics 
and prognosis was analyzed. Fisher’s test pointed out an association between IGF-1R 
and T2E expression in clinical samples (p=0,008). Particularly, patients harboring the 
fusion gene showed higher IGF-1R mRNA levels, in keeping with the increased binding 
of ERG to the IGF-1R promoter observed in the experimental models. No other 
statistically significant correlations were found.  
Kaplan-Meier and Log-rank tests were applied in order to evaluate the prognostic role 
of IGF system components for both biochemical progression free survival (BPFS) and 
clinical progression free survival (PFS) (Table 5). The analysis pointed out a 
statistically significant association between high expression of IGF-1 and good BPFS or 
PFS while a borderline association was evidenced between high expression of IGF-1R 
and better BPFS. IGF-1 expression but not IGF-1R expression was significant in the 
Cox proportional hazard multivariable analysis (hazard ratio (HR): 0,62. IC 95% [0,41-
0,94],  p=0,026) respect to BPFS. Since IGF-1R was found associated with the presence 
of the T2E translocation both in cell lines and in patients, the series was divided 
depending on the status of the fusion gene thus identifying two cohorts of patients: T2E-
positive or –negative, respectively. In the two groups, IGF-1R, IR, IGF-1 and IGF-BP3 
gene expression was classified in “high”, if the RQ value was above the first quartile, 
and “low” expression, if RQ value was below the first quartile. Then, association with 
clinico-pathological features and prognosis were assessed (Tables 6 and 7). No 
association with clinico-pathological characteristics was found in any of the two groups. 
Interestingly, Kaplan-Meier analysis evidenced that prognostic value of IGF-1R was 
statistically stronger in T2E-negative patients (p-value = 0,016) while it was not 
associated with survival in T2E-postive subgroup (p-value > 0,5). More in detail, the 
analysis pointed out that in patients negative for the fusion gene, a lower expression of 
IGF-1R confers a worse prognosis considering BPFS. This results further underlies the 
importance of T2E in establishing subgroups of patients with different prognosis. IGF-1 
was found associated with BPFS and PFS in all of the subgroups (Figure 22).  
Accordingly to multivariate analysis, nor IGF-1 or IGF-1R represent independent 
variables influencing prognosis in T2E-positive or –negative subgroups.     
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Figure 22. Prognostic value of IGF-1R and IGF-1 transcripts on BPFS of primary 
PCa patients undergone radical prostatectomy without previous treatment. The total 
series was divided into two groups depending if T2E was expressed or not. 
Comparison of survival curves was performed by the log rank test. Time scale refers 
to months from diagnosis. Thick lines indicate high expressing patients. BPFS, 
biochemical progression free survival. 
 
 
4.2 Protein expression of IGF-1R, IR and ERG in primary PCa tissues and 
association with prognosis 
 
Protein expression of IGF-1R, IR and ERG was analyzed in 243 cases from the same 
series (Table 2). Expression of IGF-1R in primary PCa tissues was not detectable in 
21/243 cases and negative in 12/222 of the samples (5%). Among the positive cases, 
85% was classified as high-expressors (165/210). IR was found not detectable in 17/243 
cases and negative in 51/226 of the samples (22,5%). Among the positive cases, 34% 
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was classified as high-expressors (76/226 ). ERG expression was not detectable in 
24/243 and negative in 85/219 cases (39%) and  85% of them was classified as high-
expressors. Interestingly, a statistically significant correlation was found between ERG 
protein levels and classical T2E evaluation reported in Material and Methods section (p 
< 0.0001, Fisher’s test). In addition, IGF-1R protein levels were significantly associated 
with mRNA levels (p=0.047, Fisher’s test). IGF-1R was associated with ERG protein 
levels (p<0.0001; Fisher’s test), further verifying the association between IGF-1R and 
T2E (Figure 23), but no other association was evidenced. Kaplan-Meier analysis was 
performed in the whole series as well as in ERG-positive and-negative groups but no 
association with BPFS or PFS was found at protein level (Tables 8, 9 and 10).  
 
 
Figure 23. Representative expression of ERG (top) and IGF-1R (bottom) in prostate cancer 
tissue array samples by immunohistochemistry (magnification, x40). The cases were classified 
as ‘high-expressors’ when medium or high positivity was present and ‘low-expressors’ when no 
staining or low positivity was observed. 
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5. TMPRSS2-ERG and CD99 molecule 
 
5.1 Preliminary data 
 
Preliminary data, previously obtained in the laboratory where this work has been 
conducted, evidenced that CD99 acts as putative oncosuppresor in PCa. PC-3 cell line 
was stably transfected for over-expression of CD99wt, as shown in figure 24. 
Transfectant cells displayed an attenuate phenotype as demonstrated by a reduced 
anchorage-independent growth (soft-agar assay) and a decreased migration capability 
when compared to non treated or empty vector transfectant cell lines.   
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Figure 24. CD99 acts as an oncosuppressor in PCa cells. PC-3 cells were transfected for 
CD99wt and its over-expression was evaluated by western blotting (top). Migratory 
features of PC-3 parental and transfected cells (bottom right).  Growth in soft-agar of 
PC-3 and clones (bottom left) [347]. 
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In vivo, PC-3 cells over-expressing CD99 showed a minor tumor incidence and a 
decreased number of extrapulmonary metastases in mice as well as a higher tumor 
latency with respect to parental cells [347] (Figure 25). 
 
 
 
 
 
         
 
Figure 25. CD99 inhibits PCa cell metastatization in mice [347].     
 
 
 
 
Clinical relevance of this data was confirmed by CD99 immunohistochemical analysis 
performed in prostate tissues spanning from hyperplasias to primitive tumor and 
metastases. In patients, CD99 expression was higher in benign lesion (70% positivity) 
when compared to primitive (12,5% positivity) or metastases (30% positivity) tissues 
(Figure 26). 
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Figure 26. CD99 evaluation by immunohistochemistry in 
patients. a) Benign prostatic hyperplasia b) Prostate 
adenocarcinoma grade II c) Prostate adenocarcinoma 
grade III d) Bone mestatasis from prostate cancer.  
 
As described in introduction section, the primary site for PCa metastasis is bone and 
different factors take part in establishing this process including “homing” events, 
capability to stimulate osteoblastic lineage and osteomimicry aptitude of PCa cells. A 
preliminary clue indicating a putative role of CD99 in PCa bone metastasis was 
obtained in this laboratory demonstrating particularly that PC-3 cells over-expressing 
CD99 showed an overall down-regulation of genes involved in osteoblastic 
differentiation. The results were obtained by GeneCARDs analysis showing that PC-3 
cells over-expressing CD99 showed a lower expression of genes involved in 
ossification, mineralization, bone development, cell-cell adhesion, cell-matrix adhesion, 
matrix proteases and proteases inhibitors and transcription factors. Accordingly, 
expression of proteins involved in osteoblastic differentiation were found higher in 
primitive or metastases PCa lesions compared to benign lesions. Representative 
immunohistochemistry images of the analyzed biomarkers including osteopontin, bone 
sialoprotein, osteonectin and osteocalcin are shown in figure 27. Percentages of 
positivity in the analyzed series is reported in table 4.  
 
 
a) b) 
c) d) 
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Table 4. Percentages of cases positive for osteoblastic differentiation markers.  
% of positive 
cases 
Osteopontin 
 
Bone sialoprotein 
 
Osteonectin 
 
Osteocalcin 
Hyperplasias 40 30 0 50 
Primitive  72 53 80 77 
Metastasis 78 50 40 60 
 
 
 
 
Figure 27. Immunohistochemical analysis of osteoblastic differentiation markers in 
hyperplasias, primitive tumor and metastasis.    
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5.2 Analysis of CD99 association with survival in primitive PCa samples  
 
In this section of the study, CD99 expression levels were analyzed in a large cohort of  
primitive PCa specimens both at gene and protein levels (Table 2). Subsequently, 
correlation between CD99 expression and clinico-pathological parameters as well as 
BPFS or PFS was investigated. Studies focused on CD99 prognosis value are limited 
and particularly none of them was related to PCa. 
Gene expression of CD99 was evaluated in a retrospective series of 270 primary 
prostate tumors by Real-Time PCR. Comparison with normal prostate tissues revealed a 
slight lower expression of CD99 in tumor  compared to healthy tissues (median value= 
0,83 ; range=0,2-2,28) (Figure 28).  
 
 
 
Figure 28. CD99 expression profile in prostate cancer patients.     
 
Expression of CD99 was classified in “high” and “low” expression depending on if 
obtained RQ value was above or below the first quartile, respectively. The association 
with clinico-pathological characteristics and prognosis was analyzed. Fisher’s test 
pointed out an association, marginal at best, between CD99 and T2E expression 
(p=0,054). Particularly, patients harboring the fusion gene showed higher CD99 mRNA 
levels. In addition, CD99 loss was found associated with positivity of margins (p= 
0,034, Fisher’s test), index of a more aggressive disease and in accordance to 
preliminary data indicating a role of CD99 in mestastatic process.  
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Kaplan-Meier and Log-rank tests were applied in order to evaluate the prognosis role of 
CD99 for both BPFS and PFS (Table 5). The analysis pointed out that CD99 is not 
statistically associated with survival but a trend of the curves indicated that higher 
expression of CD99 confers a slight better outcome accordingly to the indicated 
oncosuppressive value of CD99 in PCa (Figure 29).  
 
 
 
 
BPFS
P= 0,074
 
Figure 29. CD99 expression and association with 
BPFS or PFS in PCa. Time scale refers to months 
from diagnosis. Thick lines indicate high 
expressing patients. BPFS, biochemical 
progression free survival.    
 
 
 
 
Since CD99 was found associated with T2E translocation, the series was divided 
depending on the status of the fusion gene and CD99 gene expression was classified in 
“high”, if the RQ value was above the first quartile, and “low” expression, if RQ value 
was below the first quartile in the two groups. Fisher’s test pointed out no association 
with clinico-pathological features or BPFS and PFS in any of the two groups.  
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At protein level, CD99 was analyzed by Tissue Microarray in the retrospective series of 
243 cases. Expression of CD99 in primary PCa tissues was detected in 23/243 samples. 
Among the positive cases, 42% was classified as high-expressors (94/220). Among 
clinico-pathological parameters, CD99 was associated with ERG protein levels (p < 
0,01  Fisher’s test), as T2E-positive cases correlated with higher CD99 expression. 
Kaplan-Meier analysis was performed in the whole series as well as in ERG-positive 
and-negative groups but no association with BPFS or PFS was found at protein level.   
 
 
 
 
5.3  Analysis of CD99 expression in PCa cell lines  
  
CD99 gene and protein levels were investigated in a panel of PCa cell lines including 
malignant VCaP, DU-145, PC-3, LNCaP, 22RV1 and the non-malignant RWPE-1 cells. 
As shown in figure 30, CD99 was found similarly expressed between PCa cells and 
RWPE-1 cells with exception of LNCaP and 22RV1 cells which particularly displayed a 
consistent down-modulation of CD99 at mRNA level. No remarkable difference was 
noticed in VCaP cells at basal level compared to other cell lines. 
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Figure 30. Real Time-PCR (top) and western blotting 
(bottom) analysis of CD99 in prostate cancer cells. 
 
 
 
5.4 In vitro analysis of ETS rearrangements/CD99 correlation 
 
Considering data obtained in patients, VCaP cells were transiently transfected with ERG 
siRNA and CD99 expression was investigated to better elucidate a putative correlation 
between fusion gene and CD99. Interestingly, 48 hours silencing of ERG induced a 
down-regulation of CD99 at protein level but no modulation of CD99 transcript was 
found (Figure 31). These data better reflect results obtained in patients highlighting a 
stronger correlation between CD99 and ERG at protein level more than at mRNA level. 
ETS rearrangements appear to be able to influence CD99 expression but no through a 
direct transcriptional regulation. Accordingly, anti-ERG ChIP analysis was performed 
in VCaP and PC-3 cells as well as in RWPE-1_ERG or empty vector transfected cells 
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and qRT-PCR was perform to evaluate recruitment to CD99 promoter. As shown in 
figure 32, a fraction of ERG was actually found to bind CD99 gene promoter but the 
amount of binding was not different in VCaP and RWPE-1_tERG models compared to 
PC-3 or RWPE-1 empty vector transfected cells.  
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Figure 31. ERG influences CD99 at protein level but not at mRNA 
level. siRNA knockdown of ERG (siERG) in VCaP was assessed by 
western blotting analysis. mRNA and protein expression of CD99 was 
evaluated by Real Time-PCR (bottom left) and western blotting (bottom 
right), respectively. A representative experiment is shown.  
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Figure 32. ChIP assay was performed on VCaP and PC-3 prostate cancer cells, 
as well as on tERG- or empty vector-transfected RWPE-1 cells. ERG was 
precipitated with an anti-ERG-1/2/3 antibody. The results were obtained by 
quantitative RT-PCR. The data represent the recovery of each DNA fragment 
relative to the total input DNA. A representative experiment is shown.  
 
 
 
 
As a further confirmation of the marginal or indirect role of ERG in regulating CD99 at 
transcriptional levels, trabectedin treatment in VCaP or PC-3 cell lines did not affect 
ERG binding to CD99 promoter (Figure 33).   
Conversely, previous data in ES showed that EWS-FLI1 actually is able to bind CD99 
promoter thus regulating its expression [94]. Accordingly, trabectedin treatment in TC-
71 and 6647 ES cell lines induced a displacement of the chimera from CD99 promoter 
(Figure 34). 
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Figure 33. Trabectedin reduces ERG binding to PIM-1 but not CD99 promoter in 
VCaP cell line after 1 hour of treatment. Results were obtained by quantitative RT-
PCR and data are reported as fold enrichment over the control. ** p<0.001, 
Student’s t test. 
 
 
 
 
Figure 34. Trabectedin induces detachment of EWS-FLI1 from CD99 promoter. 
ChIP assay results were obtained by quantitative RT-PCR and data are reported as 
fold enrichment over the control. * p<0.05; ** p<0.001, Student’s t test. 
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Table 5. BPFS and clinical PFS log rank and Cox regression tests in primary PCa analyzed by qRT-
PCR.  
Total cases Biochemical Progression Clinical Progression
Parameter
No. 
Pts
No. Events 
(% BPFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
No. Events 
(% PFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
Age 0,245 0,379
≤ 55 15 5 (64,2) 3 (79,4)
56-65 81 43 (25,7) 29 (50,1)
66-75 138 58 (45,4) 34 (69,8)
> 75 36 18 (48,6) 8 (59,2)
Gleason-sp: < 0,0001 0,001 < 0,0001 0,015
2-6 109 35 (56,4) 1 17 (77,3) 1
7 129 64 (28,7) 2,96 (1,66-5,29) 43 (57,4) 3,03 (1,4-6,53) 0,005
Greater than 7 32 25 (11,7) 1,9 (1,16-3,11) 14 (0) 1,57 (0,83-2,96) 0,163
PSA (ng/ml): < 0,0001 0,025 0,082
10 or less 154 57 (47,1) 1 34 (69)
10-20 74 37 (40,2) 1,98 (1,2-3,25) 24 (54,3)
Greater than 20 40 29 (23,3) 1,46 (0,86-2,48) 15 (55,9)
cT: < 0,0001 0,029 1 0,002
cT2b or less 248 108 (42,3) 1 < 0,0001 66 (63,1) 2,46 (1,38-4,4)
cT3a or greater 21 16 (14,5) 2,57 (1,62-4,06) 8 (58,6)
pT: < 0,0001 Not significant 0,001 Not significant
pT2 or less 135 43 (57,4) 25 (77,9)
pT3 or greater 135 81 (22,1) 49 (48,4)
pN: < 0,0001 Not significant 0,2
pN0 236 105 (42,4) 64 (63,6)
pN1 or greater 12 11 (8,3) 5 (50,9)
Margins: < 0,0001 0,001 < 0,0001 0,039
Negative 137 40 (56) 1 24 (77) 1
Positive 133 84 (20,4) 2,11 (1,36-3,28) 50 (41,6) 1,74 (1,02-2,95)
TMPRSS2/ERG 0,119 0,957
Negative 92 49 (32,5) 26 (63,9)
Positive 178 75 (44,3) 48 (61,6)
IGF-1R 0,051 Not significant 0,835
Low 67 34 (45,3) 17 (70,3)
High 203 90 (41,2) 57 (61,4)
IR 0,974 0,632
Low 66 29 (52,1) 17 (69,9)
High 199 93 (37,6) 57 (59,5)
IGF-1 < 0,0001 0,026 0,002 Not significant
Low 67 44 (18,2) 1 26 (41,5)
High 202 79 (47,2) 0,62 (0,41-0,94) 47 (68,6)
IGFBP-3 0,599 0,943
Low 67 32 (43,1) 17 (61,3)
High 203 92 (39,5) 57 (62,9)
CD99 0,074 0,657
Low 67 36 (28,3) 18 (70,6)
High 203 88 (43,4) 56 (60,5)
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Table 6. BPFS and clinical PFS log rank and Cox regression tests in patients with PCa and TMPRSS2-
ERG fusion gene expression analyzed by qRT-PCR.   
T2-ERG + Biochemical Progression Clinical Progression
Parameter
No. 
Pts
No. Events 
(% BPFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
No. Events 
(% PFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
Age 0,787 0,63
≤ 55 10 4 (56) 2 (78,8)
56-65 59 28 (22) 20 (51,2)
66-75 82 31 (58,9) 21 (67,6)
> 75 27 12 (54,1) 5 (68,8)
Gleason-sp: < 0,0001 < 0,0001 0,01 Not significant
2-6 72 20 (64,3) 1 13 (71,2)
7 90 43 (22,2) 6,32 (2,73-14,4) < 0,0001 29 (57,2)
Greater than 7 16 12 (25) 4,03 (1,91-8,47) < 0,0001 6 (52,2)
PSA (ng/ml): 0,001 0,001 0,021 0,035
10 or less 101 35 (51,6) 1 20 (73,1) 1
10-20 48 21 (38,9) 3,66 (1,89-7,09) < 0,0001 16 (42,2) 2,53 (1,11-5,74) 0,027
Greater than 20 27 18 (29,3) 2,07 (1,04-4,14) 0,038 11 (47,2) 1,17 (0,51-2,69) 0,703
cT: 0,078 < 0,0001 0,053 < 0,0001
cT2b or less 167 69 (44,6) 1 44 (61,6) 1
cT3a or greater 10 6 (7,5) 3,63 (1,86-7,09) 4 (58,3) 5,49 (2,15-14)
pT: < 0,0001 Not significant 0,003 Not significant
pT2 or less 86 22 (73,1) 14 (79)
pT3 or greater 92 53 (20,6) 34 (44,8)
pN: < 0,0001 Not significant 0,468
pN0 156 62 (46,8) 41 (63,4)
pN1 or greater 6 6 (0) 2 (50)
Margins: < 0,0001 0,028 0,031 Not significant
Negative 97 29 (57,9) 1 20 (72,4)
Positive 81 46 (20,1) 1,87 (1,06-3,27) 28 (30,4)
IGF-1R 0,889 0,198
Low 44 17 (60) 7 (82,1)
High 134 58 (43,1) 41 (57,5)
IR 0,953 0,689
Low 44 18 (55,7) 11 (68,7)
High 132 57 (42) 37 (59,4)
IGF-1 < 0,0001 Not significant 0,035 Not significant
Low 44 27 (16,5) 16 (28)
High 134 48 (53,3) 32 (69,8)
IGFBP-3 0,679 0,898
Low 44 19 (50,8) 11 (69,4)
High 134 56 (41,6) 37 (58,8)
CD99 0,458 0,862
Low 44 19 (53,1) 11 (72,9)
High 134 56 (43,2) 37 (59,1)
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Table 7. BPFS and clinical PFS log rank and Cox regression tests in patients with PCa and  no TMPRSS2-
ERG fusion gene expression analyzed by qRT-PCR.   
T2-ERG - Biochemical Progression Clinical Progression
Parameter
No. 
Pts
No. Events 
(% BPFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
No. Events 
(% PFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
Age 0,108 0,402
≤ 55 5 1 (80) 1 (80)
56-65 22 15 (23,9) 9 (45,9)
66-75 56 27 (29,1) 13 (73)
> 75 9 6 (33,3) 3 (37,5)
Gleason-sp: 0,001 < 0,0001 0,002 Not significant
2-6 37 15 (43,1) 1 4 (85,7)
7 39 21 (39) 6,32 (2,73-14,4) < 0,0001 14 (57)
Greater than 7 16 13 (0) 4,03 (1,91-8,47) < 0,0001 8 (0)
PSA (ng/ml): 0007 0,001 0,937 0,035
10 or less 53 22 (38,3) 1 14 (63) 1
10-20 26 16 (27,6) 3,66 (1,89-7,09) < 0,0001 8 (62,6) 2,53 (1,11-5,74) 0,027
Greater than 20 13 11 (15,4) 2,07 (1,04-4,14) 0,038 4 (68,4) 1,17 (0,51-2,69) 0,703
cT: 0,007 < 0,0001 0,192 < 0,0001
cT2b or less 81 39 (37,4) 1 22 (64,8) 1
cT3a or greater 11 10 (0) 3,63 (1,86-7,09) 4 (60) 5,49 (2,15-14)
pT: 0,005 Not significant 0,140 Not significant
pT2 or less 49 21 (38,2) 11 (75,7)
pT3 or greater 43 28 (26) 15 (52,5)
pN: 0,041 Not significant 0,280
pN0 80 43 (34) 23 (63,3)
pN1 or greater 6 5 (16,7) 3 (50)
Margins: < 0,0001 0,028 0,001
Negative 40 11 (53,9) 1 4 (87,6)
Positive 52 38 (17,4) 1,87 (1,06-3,27) 22 (43,7)
IGF-1R 0,016 0,099
Low 23 15 (34,8) 9 (58,9)
High 69 34 (35,3) 17 (67,2)
IR 0,217 0,423
Low 22 9 (54,5) 5 (75,9)
High 67 38 (25,4) 21 (58)
IGF-1 0,001 Not significant 0,012 Not significant
Low 22 17 (14,9) 10 (51,1)
High 69 31 (38,3) 15 (69,3)
IGFBP-3 0,832 0,768
Low 23 11 (46,5) 5 (75,9)
High 69 38 (31,3) 21 (62,1)
CD99 0,395 0,658
Low 23 15 (16,9) 7 (66,1)
High 69 34 (40,2) 19 (62,8)
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Table 8. BPFS and clinical PFS log rank and Cox regression tests in primary PCa analyzed by IHC.  
Total cases IHC Biochemical Progression Clinical Progression
Parameter
No. 
Pts
No. Events 
(% BPFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
No. Events 
(% PFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
Gleason-sp: < 0,0001 < 0,0001 < 0,0001 Not significant
2-6 87 26 (57,7) 1 12 (78,8)
7 123 60 (29,5) 4,46 (2,39-8,33) 41 (57,5)
Greater than 7 29 23 (11,5) 2,84 (1,68-4,8) 11 (29)
PSA (ng/ml): < 0,0001 0,05 0,12
10 or less 132 49 (45,5) 1 28 (69,4)
10-20 69 34 (40,5) 2,26 (1,38-3,73) 23 (52,3)
Greater than 20 36 25 (26,4) 1,66 (0,98-2,82) 12 (60,3)
cT: < 0,0001 < 0,0001 0,250
cT2b or less 219 95 (41,4) 1 58 (62,8)
cT3a or greater 19 14 (17,6) 2,52 (1,59-4) 6 (63,2)
pT: < 0,0001 0,013 Not significant
pT2 or less 115 37 (55,9) 22 (77,3)
pT3 or greater 124 72 (23,4) 42 (50,1)
pN: < 0,0001 0,253
pN0 209 91 (42,2) 55 (64)
pN1 or greater 10 10 (0) 4 (50)
Margins: < 0,0001 0,01 < 0,0001 0,008
Negative 116 33(54,8) 1 19 (77,9) 1
Positive 123 76(21,5) 2,11 (1,36-3,27) 45 (41) 2,11 (1,21-3,69)
ERG intensity 0,366 0,257
Negative 101 50 (23,7) 31 (59,7)
Positive 114 53 (42,2) 30 (61,1)
IGF-1R intensity 0,945 0,939
Low expressors 53 25 (35,5) 15 (66,8)
High expressors 165 79 (34,6) 46 (59,3)
IR intensity 0,265 0,566
Low expressors 148 66 (41,7) 39 (66,8)
High expressors 74 37 (32,8) 21 (51,4)
CD99 intensity 0,915 0,802
Low expressors 123 58 (30,9) 34 (62,9)
High expressors 93 44 (43,1) 26 (60,1)
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Table 9. BPFS and clinical PFS log rank and Cox regression tests in patients with PCa and 
TMPRSS2-ERG positive analyzed by IHC. 
ERG Positive Biochemical Progression Clinical Progression
Parameter
No. 
Pts
No. Events 
(% BPFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
No. Events 
(% PFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
Gleason-sp: <0,0001 0,003 0,001 Not significant
2-6 43 13 (59,6) 1 5 (78,6)
7 61 32 (30,9) 5,98 (2,15-16,6) 24 (45,8)
Greater than 7 10 8 (20) 3,16 (1,29-7,75) 1 (87,5)
PSA (ng/ml): <0,0001 0,002 0,079
10 or less 63 21 (56,8) 1 11 (73,5)
10-20 32 16 (38) 3,98 (1,86-8,47) 12 (45,8)
Greater than 20 19 16 (0) 2,39 (1,10-5,18) 7 (52,7)
cT: <0,0001 Not significant 0,006 0,048
cT2b or less 34 7 (74,1) 3 (85,6) 1
cT3a or greater 79 46 (28,7) 27 (50,8) 3,42 (1-1,16)
pT: 0,006 Not significant 0,077
pT2 or less 56 18 (64,8) 10 (76,3)
pT3 or greater 58 35 (23,2) 20 (48,6)
pN: 0,001 Not significant 0,906
pN0 92 40 (47,2) 23 (62,7)
pN1 or greater 6 6 (0) 2 (66,7)
Margins: <0,0001 0,006 0,04 Not significant
Negative 59 17 (65) 1 11 (74,3)
Positive 55 36 (12,9) 2,65 (1,33-5,29) 19 (39,4)
IGF-1R intensity 0,654 0,977
Low expressors 10 4 (60) 3 (65,6)
High expressors 104 49 (39,9) 27 (60,5)
IR intensity 0,845 0,618
Low expressors 67 31 (45,1) 19 (61,8)
High expressors 47 22 (37,4) 11 (62,4)
CD99 intensity 0,175 0,610
Low expressors 62 32 (33,3) 18 (45,4)
High expressors 51 20 (50,9) 13 (65,2)
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Table 10. BPFS and clinical PFS log rank and Cox regression tests in patients with PCa and 
TMPRSS2-ERG negative analyzed by IHC. 
ERG Negative Biochemical Progression Clinical Progression
Parameter
No. 
Pts
No. Events 
(% BPFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
No. Events 
(% PFS)
Univariate 
p Value HR (95% CI)
Multivariate
P Value
Gleason-sp: 0,003 Not significant 0,014 Not significant
2-6 32 11 (32,7) 6 (77,4)
7 53 27 (23,7) 16 (66,3)
Greater than 7 16 12 (15,6) 9 (0)
PSA (ng/ml): 0,810 0,929
10 or less 52 25 (16,9) 17 (55,7)
10-20 32 16 (43,6) 9 (66,1)
Greater than 20 15 8 (44,4) 4 (71,4)
cT: 0,011 Not significant 0,055 Not significant
cT2b or less 93 44 (25,2) 10 (52,6)
cT3a or greater 8 6 (15) 21 (55,9)
pT: 0,013 Not significant 0,226
pT2 or less 43 16 (30,2) 11 (72,2)
pT3 or greater 58 34 (18,7) 20 (46,9)
pN: < 0.0001 < 0,0001 0,088
pN0 93 45 (24,5) 1 29 (60,1)
pN1 or greater 4 4 (0) 21,73 (6,36-71,42) 2 (0)
Margins: 0,003 0,003 0,01 0,015
Negative 43 14 (23,1) 1 7 (78,6) 1
Positive 58 36 (31,3) 2,71 (1,41-5,23) 24 (38,5) 2,87 (1,23-6,71)
IGF-1R intensity 0,786 0,45
Low expressors 43 21 (25,7) 12 (68)
High expressors 58 29 (22,1) 19 (55,8)
IR intensity 0,06 0,08
Low expressors 74 33 (35,6) 20 (68,9)
High expressors 25 15 (27,9) 10 (0)
CD99 intensity 0,078 0,64
Low expressors 58 25 (29,2) 17 (66,7)
High expressors 41 24 (29,8) 13 (44,5)
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Discussion 
 
Several studies have pointed out the relevance of ETS family of transcription factors in 
pathogenesis and progression of several cancers. ETS proteins act as gene activators or 
repressors, regulating genes involved in proliferation, differentiation, apoptosis, 
metastasis, tissue remodeling, and angiogenesis. Expression of ETS genes has been 
found altered both in leukaemias and solid tumors and, particularly, an aberrant 
expression due to chromosomal translocations has been described as a common feature 
of different tumor types including ES, PCa and acute myeloid leukaemia. Presence of 
tumor-specific fusion genes represents a potential opportunity in clinic for identification 
of diagnosis or prognosis biomarkers and pharmacologic intervention to therapeutic 
benefit. More recently, interest in ETS-driven diseases has been further supported by 
finding that several chemotherapeutic drugs including cytarabine, doxorubicin [366] and 
etoposide [367] induce an ETS-attenuation gene expression signature while resulting in 
significant co-morbidities, including organ-toxicity, such as cardiomyopathy, or second 
malignancy due to shared molecular mechanisms between tumor and normal tissues 
[368, 369]. Taken together these evidences highlight the importance of transversal 
studies to unravel shared or distinct target genes, pathways and mechanisms of 
regulation in ETS-driven diseases. In this study, ES and PCa have been considered in 
order to identify common or distinctive mechanisms determined by ETS 
rearrangements. Particularly, impact of EWS-FLI1, the hall mark of ES, and 
TMPRSS2-ERG, in PCa, has been investigated on the IGF system and CD99 molecule. 
In ES, EWS-FLI1 has been demonstrated to regulate transcription of some IGF system 
components, including IGF-1 and IGFBP-3, acting as gene activator and repressor, 
respectively, as well as CD99 promoter. It has been recently demonstrated that ETS-
positive prostate tumors display a greater under-expression of IGFBP-3 compared to 
ETS-negative [370]. The presented results demonstrate for the first time that IGF-1R 
represents a common target of ETS rearrangements.  
ChIP analysis showed ERG and FLI1 binding to the IGF-1R gene promoter, suggesting 
a direct transcriptional regulation of IGF-1R by tERG in PCa or EWS-FLI1 in ES. 
Possibility to have common deregulated genes is in line with previous evidences 
demonstrating that tERG, EWS-ERG or FUS/ERG actually significantly up-regulate the 
transcript of more than 100 common genes, including PIM-1, in the NIH-3T3 cell line 
[174]. In PCa, a greater ERG recruitment to IGF-1R promoter was found in VCaP cells 
compared to PC-3 or in RWPE-1_tERG compared to empty vector. In addition, 
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androgen deprivation induced by abiraterone acetate treatment in the androgen-
responsive VCaP cells caused a decrease in the expression of ERG, as previously 
reported [371], but also an inhibition of IGF-1R confirming the presence of a 
TMPRSS2-ERG/IGF-1R androgen-regulated axis. The relationship between T2E and 
IGF-1R was also confirmed in radical prostatectomy specimens; patients expressing the 
fusion gene exhibited higher IGF-1R expression. TMPRSS2-ERG represents an early 
event in prostate cancer but its expression is maintained from primary tumor cells to 
metastatic cells [372]. Considering that RWPE-1 is a model of non-tumorigenic 
immortalized cells while VCaP cells are representative of advanced disease, the data 
indicate that TMPRSS2-ERG/IGF-1R axis may represent a constant mechanism along 
the different stages of the pathology. The IGF-1R gene has been identified as a 
molecular target for a number of stimulatory transcription factors and inhibitory 
proteins with important implications in cancer. Aberrant fusion product such as EWS-
WT1, the genetic hallmarks of desmoplastic small round cell tumor, was found to act as 
transactivator for the IGF-1R gene, providing a selective growth advantage to tumor 
cells. Despite in contrast with previous evidences in literature [92], EWS-FLI1 was 
found to bind IGF-1R gene promoter indicating a transcriptional regulation. In addition, 
silencing of EWS-FLI1 was observed in parallel with down-regulation of IGF-1R 
suggesting that IGF-1R is indeed a target of EWS-FLI1. Identification of EWS-FLI1 
targets represents a key aspect in the understanding of the molecular behavior of ES. It 
is widely recognized that EWS-FLI1 cooperates with the IGF system in establishment 
of the pathology. Therefore, this study provide a crucial explanation of the elevated 
IGF-1R expression described in 70 to 80% of patients [282] and more strongly support 
the importance of EWS-FLI1 and IGF system in maintenance of ES malignancy.  
On the contrary, data from this study indicate CD99 is differentially regulated between 
ETS-related tumors as CD99 is a target of EWS-FLI1 but not of tERG. As previously 
demonstrated, within different tumors ETS rearrangements can differentially regulate 
expression of target genes like the reported KCNN2 [370]. In ES, CD99 represents a 
validated EWS-FLI1 target as the chimera was found to bind its promoter and EWS-
FLI1 forced expression in mesenchymal stem cells induced up-regulation of CD99 [94, 
373]. In PCa, CD99 acts as a  putative oncosuppressor and it did not show significant 
differences between tERG-positive and –negative cells both considering binding of 
ERG to the promoter and transcript levels. Noteworthy, CD99 expression is decreased 
in PCa in general suggesting that regulation of CD99 may be controlled by other 
mechanisms, such as promoter methylation as described for CAV1 gene in PCa [374]. In 
this study, a direct correlation was anyway found between ERG and CD99 proteins both 
in vitro and in patients. Explanation of this relationship is not easy and it would request 
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more detailed analysis but putatively suggests that ERG target genes comprehend 
regulators of CD99, possibly including miRNAs as previously demonstrated in ES 
[375]. Considering that ERG expression represents a marker of malignancy while CD99 
is associated with a benign phenotype in could be speculated that effective relevance of 
this interaction could be marginal consistently with absence of association between 
CD99 and survival.   
From the clinical standpoint, the ETS/IGF-1R mechanism appears of high interest as it 
provides basis for a more rationale use of anti-IGF-1R inhibitors in these tumor types. 
In PCa, the contribution of IGF-1R to prostate carcinogenesis and progression remains 
controversial, but epidemiological, preclinical and clinical results indicate that IGF-1R 
over-expression plays an important role in the pathogenesis of CRPC. This evidence, in 
particular, lead to the enrollment of castration-resistant prostate cancer patients in 
several clinical trials investigating the effects of IGF-1R inhibitors but the studies 
evidenced a modest effect of IGF-1R inhibition with a minority of patients experiencing 
significant benefits. Data from this study demonstrate that only PCa cells expressing the 
fusion gene and consequently higher levels of IGF-1R display a potential relevant 
sensitivity to anti-IGF-1R agents. Accordingly, ERG silencing caused a decreased 
sensitivity to the treatment. These results are in line with previous evidences 
demonstrating that PARP1 inhibitors blocked ETS-positive but not ETS-negative 
prostate cancer xenograft growth and reflect more recent evidences showing that 
treatment with ganitumab, an IGF-1R inhibitor, blocked growth of T2E-positive VCaP 
but not T2E-negative 22RV1 xenograft models [376]. In addition, ERG silencing 
determined a decreased sensitivity to abiraterone acetate, consistently with previous 
observations that T2E-positive PCa patients display a better response to anti-androgen 
therapy. In clinic, the onset of androgen receptor-linked resistance mechanisms in 
CRPC patients treated with abiraterone represents an important limitation and the 
identification of “druggable” target involved in the androgen receptor pathway represent 
an interesting opportunity to overcome the resistance. In this perspective, different 
studies have been designed in order to combine abiraterone with targeted agents 
including Src inhibitors [377] or PI3K pathway inhibitors [378]. The results provide a 
preliminary in vitro evidence regarding the benefits of a combined treatment of the 
monoclonal antibody CP-751,871 with abiraterone acetate. Particularly, in VCaP cells 
association of CP-751,871 with abiraterone acetate gave synergistic effects, supporting 
the concept of a simultaneous use of two targeted agents to deprive tERG-expressing 
cells of fundamental pathways that operate in concert to sustain cell proliferation. 
Overall, data in PCa provide a criterion for patient selection, identifying CRPC patients 
expressing TMPRSS2-ERG as good responders to anti-IGF-1R treatment. In ES, all of 
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the patients express the EWS-FLI1 chimera therefore avoiding application of a similar 
criterion in this tumor type. Anyway, presence of EWS-FLI1/IGF-1R axis provides 
rationale for combination of anti-IGF-1R agents with the newly licensed 
chemotherapeutic agent trabectedin consistently with its effects on IGF-1R expression 
levels. Trabectedin is an alkylator agent particularly toxic in sarcomas bearing 
translocations. The reason is the recently evidenced capability of   DNA binding agents 
including trabectedin but also DXR, mithramycin, and  actinomycin D to alter 
transcriptional activities of ETS rearrangements attenuating their gene signature. These 
data introduce a certain level of specificity in the action of conventional agents, 
depending on the drug itself, the transcription factor and the cellular context. 
Accordingly, trabectedin and DXR caused detachment of EWS-FLI1 chimera from its 
target promoters, including TGFβR2 and CD99, while only trabectedin enhanced EWS-
FLI1 occupancy on the IGF-1R promoter. Increased EWS-FLI1 binding to specific 
promoters represent another variable in the mechanism of action of chemotherapeutics 
and, in addition, appears peculiar of this tumor type. In PCa trabectedin was found to 
decrease binding of ERG to both PIM-1 and IGF-1R promoters without affecting 
binding to CD99 promoter evidencing the cell-specific action of this agent. These data 
are in line with previous evidences in myxoid liposarcoma where trabectedin but not 
DXR affected the binding of FUS-CHOP to target promoters [26]. In ES, increased 
binding of EWS-FLI1 to IGF-1R promoter corresponded to higher IGF-1R protein 
expression providing the rationale for a combined use of trabectedin with anti-IGF-1R 
agents.  Combination of trabectedin with the dual inhibitor IGF-1R/IR OSI-906, a small 
molecule shown to have anti-tumoral activity against several tumors, gave synergistic 
effects in the ES cell lines considered in this study. On the opposite side, no synergistic 
effect was observed in VCaP PCa cells harboring the fusion gene. Use of anti-IGF-1R 
inhibitors in ES gave satisfactory results at preclinical levels but limited effectiveness in 
clinic [379]. Use of trabectedin as single agent did not demonstrated significant activity 
in sarcomas including ES [99]. Considering the paucity of therapeutic choices in ES, 
these data demonstrate the potential benefit of a combination between trabectedin and 
anti-IGF-1R agents and provide a novel therapeutic strategy for treatment of ES 
patients.  
Understanding the clinical role of the IGF system represents an important choice to 
defeat tumor cells because different subtypes of patients may have distinct outcome and 
may require differential treatment. In this study, expression of different components of 
the IGF system was analyzed in a primary PCa series taking in account gene fusion 
presence. Overall, no relevant differential expression was found between tumor and 
normal cells except for a lower tumor expression of IGFBP-3, consistently with 
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published data. In addition, as prognostic implications of IGF system components 
expression are still controversial, association with outcome was evaluated both 
considering total cases and subgroups of patients harboring or not the fusion gene. 
Overall, the findings reported in this study support a relationship between high mRNA 
expression of  IGF-1 and IGF-1R and favorable outcome. High expression of IGF-1R 
by immunohistochemistry did not distinguish patients with different prognosis but 
immunohistochemistry has limited power in terms of antigen quantification.  
Previous studies regarding IGF-1R prognosis value reported similar results in sarcomas 
and in carcinomas. In ES, lower IGF-1 circulating levels were found in patients with 
metastatic disease [380] while in a cohort of 57 patients a relationship was found 
between high expression of IGF-1R and IGF-1 and favorable prognosis [282]. In breast 
cancer, higher expression of IGF-1R was found in tumor specimens compared to 
matched control samples [381]. Data in PCa are highly conflicting but, as previously 
reported, some of them are in accordance with a correlation between elevated IGF-1R 
activity and minor malignancy. Results from this study add another level of complexity 
because, while IGF-1 significance was maintained in all the analyzed subgroups, IGF-
1R was found to influence BPFS in the TMPRSS2-ERG-negative patients while 
marginal or no association was found in the total cases or TMPRSS2-ERG-positive 
cases, respectively. Several studies report that TMPRSS2-ERG presence defines 
patients with different biological and clinical behaviors [191]. For this reason, 
identification of molecular targets related to androgen-mediated activation of 
TMPRSS2-ERG has a relevance for the clinical management of PCa. Lesions mutually 
exclusive with presence or absence of ETS rearrangements have been found laying the 
basis for the molecular characterization of PCa, often beginning with ETS-positive and 
ETS-negative subclasses. Mutations and deletions in PTEN and p53 are enriched in 
ETS-positive tumors while mutations on SPOP, CDH1, and over-expression of SPINK1 
exclusively occur in ETS-negative tumors defining molecular subtypes of PCa [382]. 
Recently, molecular alterations in SPOP gene were found to define a new subtype of 
PCa and the prognosis value of SPOP was statistically more significant in the subgroup 
of patients without the fusion gene [179]. Accordingly, the obtained results identify the 
subgroup of ETS-negative and IGF-1R low-expressor patients as a group with a 
particularly poor biochemical progression free survival.  IGF-1R could thus represent a 
useful biomarker for patients not harboring the fusion gene alongside the parameters 
already used in clinic. IGF system sustains tumor cell proliferation, protects cells from 
apoptosis and DNA damage but also favors differentiation [218], depending on the 
cellular context. Overall, the presented results indicate IGF-1R drives different effects 
depending on the presence or absence of TMPRSS2-ERG. In case of PCa, it has been 
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already reported that TMPRSS2-ERG regulates several pathways including 
differentiation [383]. Indeed, it has been recently demonstrated that TMPRSS2-ERG 
blocks luminal cell differentiation driving proliferation [384]. As a consequence, it 
could be speculated that when TMPRSS2-ERG is expressed, IGF-1R acts in a less 
differentiated phenotype where drives proliferation while IGF-1R activity turns toward 
differentiation in presence of TMPRSS2-ERG and a more differentiated context.  These 
conclusions could be in accordance with a recent in vitro study showing that IGF-1R 
stimulation induces differentiation in non-malignant cells while induces proliferation in 
malignant cell models [385] further supporting the importance of the cellular context for 
IGF-1R activity.  
Identification of biomarkers in PCa represents an urgent need. With this perspective and 
to get more insight regarding its value in PCa, CD99 prognostic relevance was 
evaluated. Prognosis value of CD99 has been recently demonstrated in multiple 
myeloma, where its expression correlates with longer overall survival [386], and in 
osteosarcoma, where low expression of this molecule correlates with poor outcome 
[387], while no previous information was available in PCa. In this study, despite a little 
trend suggesting a correlation between CD99 expression and a better biochemical free 
progression free survival, no clinical relevance for CD99 was found in the field of 
prognostic biomarkers. In accordance to preliminary data indicating a role of CD99 in 
metastasis, the data suggest that CD99 loss could represent a relevant event in 
influencing invasiveness processes as supported by the association between CD99 and 
positivity of margins.  
 
In conclusion, this study demonstrates that IGF-1R is an important target of tERG and 
EWS-FLI1, and that this interaction has relevant translational implications both in PCa 
and in ES. In PCa, it leads to a higher IGF-1R expression both in cell lines and in 
patients providing the rationale for treating  the subpopulation of patients expressing 
T2E with anti-IGF-1R agents especially in combination with abiraterone acetate. In ES, 
trabectedin enhanced binding of EWS-FLI1 to the IGF-1R promoter, which resulted in 
increased IGF-1R expression, suggesting the criterion for development of a therapy that 
combines trabectedin with anti-IGF signaling agents. CD99 is differentially regulated 
between PCa and ES, beside ETS consensus sequences are present in its promoter 
suggesting further analysis are required. In addition it did not display prognostic value 
in PCa while IGF-1R expression discriminates patients with different outcome inside 
the subgroup of cases negative for the fusion gene. 
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